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1. Introduction
1.1 Hematopoiesis and acute myeloid leukemia (AML) 
Hematopoiesis is a regulated developmental cascade for progressive 
restriction of cell fate potentials from hematopoietic stem cells (HSCs) to 
lineage-restricted progenitors that produce all lineages of mature blood cells 
(Miyamoto et al., 2004; Shizuru et al., 2005). The HSCs, characterized by 
pluripotency and self-renewal capacity are the basis of the hematopoietic 
hierarchy that gives rise to long-term (LT) and short-term (ST) HSCs, which 
then develop into myeloid and lymphoid progenitor cells. Subsequently, these 
progenitor cells give rise to distinct mature blood cells as depicted in Figure 1. 
Acute myeloid leukemia (AML) is a malignancy  of the hematopoietic 
cells characterized by an abnormal proliferation of myeloid precursor cells, an 
inefficient activation of the apoptotic program and an arrest in cellular 
differentiation (Bonnet and Dick, 1997; Jansen et al., 1999; Lowenberg et al., 
1999; Tenen et al., 1997). A variety of leukemia also arise from mutations that 
accumulate in HSCs to cause their malignant transformation at the stage of 
stem cells or their progeny (Ferreira et al., 2005; O'Neill and Schaffer, 2004; 
Reya et al., 2001; Weissman and Baltimore, 2001). Increasing evidences 
suggest that the leukemias are sustained by leukemic stem cells (Rosenbauer 
et al., 2005). The leukemic-stem cell (LSC) hypothesis represents a modern-
day interpretation of the proposal made by Rudolph Virchow and Julius 
Cohnheim 150 years ago that the cancer results from the activation of dormant 
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embryonic-tissue remnants (Huntly and Gilliland, 2005). The LSCs share 
important stem-cell function with normal HSCs such as self-renewal, initial 
differentiation, and survival (Figure 2).
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Figure 1: Schematic representation of the main lineage commitment steps in 
hematopoiesis and transcription factors which are involved in hematopoietic 
development. The hematopoietic stem cell (HSC) is the basis of the hematopoietic 
hierarchy and gives rise to LT-HSC and ST- HSC and which gives multilineage progenitors 
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(MLP), which can differentiate into all the hematopoietic lineages. MLPs become lineage 
restricted to the lymphoid and myeloid lineages in the common lymphoid progenitor (CLP) 
and common myeloid progenitor (CMP), respectively. CLPs can give rise to B and T cells, 
while CMPs can give rise to megakaryocyte-erythrocyte progenitors (MEP) and 
granulocyte-monocyte progenitors (GMP). (Reya et al., 2001; Weissman and Baltimore, 
2001).
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Figure 2: Leukemic stem-cell hypothesis. Both normal HSCs and neoplastic LSCs have 
the ability to self-renew and initially differentiate into less pluripotent daughter cells. 
However, HSCs produce short-lived progenitors such as CMPs and GMPs, which 
terminaly differentiate into mature monocyte and granulocytes, In contrast, LSCs give rise 
to leukemic blasts, which harbour a block in their terminal differentiation (Rosenbauer et
al., 2005)
AML is not a single disease but a group of neoplasms with diverse 
genetic abnormalities and variable responses to treatment. Based on 
cytogenetic and molecular analyses three major groups of AML subtypes can 
be discriminated. One comprises AML with balanced chromosomal 
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aberrations, such as t(8;21), inv(16) and t(15;17). The second group includes 
cases with unbalanced, mostly numeric chromosomal aberrations frequently 
involving chromosomes 5, 7 and 8. The third group consists of patients with 
no detectable abnormalities (Hiddemann W; 2003). Balanced chromosomal 
translocations are the most specific genetic lesions in AML and may represent 
critical, early events in the genesis of the leukemic clone. The most common 
translocations are listed in the Table 1. In addition to the chromosomal 
abnormalities, aberrant expression of the lineage specific transcription factors 
plays an important role in the pathogenesis of AML through activation or 
repression of genes regulating proliferation and differentiation (Mills et al., 
2000).
 Table 1. Common translocations in AML (Lowenberg et al., 1999)
Translocation Genes Involved Morphology
t(8;21)(q22;q22) AML1/ETO M2 (90%), Mild narrow 
eosinophilia
t(16;21)(q24;q22)
t(3;21)(q26;q22)
AML1/MTG16
AML1/EV11
Variable
Variable
Inv(16)(p13;q22) CFBβ/MYH11 M4Eo (almost exclusively), rarely 
M4, M5, M2 also with abnormal 
marrow eosinophilia
t(16;16)(p13;q22)
del(16)(q22)
CFBβ/MYH11
CFBβ?
As for inv (16)
M4, M2 (probably no)
M4Eo with out CFBβ/MYH1
t(15;17)(q22;q12) PML/RARα M3 (exclusively)
t(11;17)(q23;q12) PLZF/RARα M3 (exclusively)
t(5;17)(q35;q12)
t(11;17)(q13;q12)
t(17;17)(q11;q12)
t(4;11)(q21;q23)
NPM/ RARα
NuMA/ RARα
STAT5b/RARα
MLL/AF4
M3 (exclusively)
M3 (exclusively)
M3 (exclusively)
Most commonly associated with 
infant ALL
t(6;11)(q27;q23) MLL/AF6 M4 or M5 (& T-ALL)
t(9;11)(q22;q23) MLL/AF9 M4 or M5
5
t(11;19)(q23;p13;3) MLL/ENL Biphenotypic; Pre-B
ALL; M4 or M5
t(11;19)(q23;p13.1)
t(11;19)(q23;p13.3)
t(11;16)(q23;p13)
MLL/ELL
MLL/EEN
MLL/CBP
M4 or M5
M4 or M5
M4 or M5 ,occasional 
dyserythropoiesis
t(11;22)(q23;p13) MLL /p300
t(7;11)(p15;p15) NUP98/HOXA9 M2 or M4
t(2;11)(q31;p15) NUP98/HOXD13 Variable
t(1;11)(q24;p15) NUP98/PMX1 M2
inv(11)(p15;q22)
t(6,9)(p23;q34)
NUP98/DDX10
DEK/CAN
(NUP214)
M2 or M4, bone marrow basophilia, 
myelodysplasia with ringed 
sideroblasts
t(18;16)(p11;p13) MOZ/CBP FAB M4 or M5, bone marrow 
erythropagocytosis
t(9;22)(q34;q11)
t(3;3)(q21;q26)
BCR/ABL
EVI-1 (overexpression)
M1 or M2
Megakaryocytic dysplasia and often 
trilineage dysplasia 
inv(3)(q21;q26) EVI-1 (overexpression) Megakaryocytic dysplasia and often 
trilineage dysplasia
t(16;21)(p11;q22) TLS/ERG Variable FAB; extensive bone 
marrow hemophagocytosis
del(17p) p53 mutations Characteristic dysgranulopoiesis
1.2 Acute promyelocytic leukemia (APL) and role of PML-RARα in   
leukemogenesis
Acute promyelocytic leukemia (APL), which represents 10% of acute myeloid 
leukemia, is characterized by an accumulation of malignant promyelocytes 
that fail to differentiate into normal granulocytes. (Douer, 2002; Warrell et al., 
1994). APL is specifically associated with the chromosomal  translocation 
t(15;17)(q22;q21), which generates a PML-RARα fusion between the genes 
of a nuclear protein, promyelocytic leukemia (PML), and that of a 
transcription factor, retinoic acid receptor α (RARα) (Lallemand-Breitenbach 
et al., 1999; Warrell, 1993; Warrell et al., 1993). PML-RARα which is the 
molecular signature of APL, plays a crucial role in leukemogenesis by acting 
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as a dominant-negative factor thereby disrupting the wild-type functions of 
both the PML and the RARα pathways (Kakizuka et al., 1991; Melnick and 
Licht, 1999). Both the in-vivo analysis in transgenic animals and the in-vitro
analysis in hematopoietic cells have demonstrated that the PML-RARα fusion 
protein contributes to the leukemic phenotype by inhibiting differentiation and 
promoting survival of hematopoietic precursor cells (Wang et al., 1998b; 
Zhong et al., 2000). 
Different mechanisms are proposed to explain how PML-RARα blocks 
differentiation. The fusion protein is able to silence natural RAR targets which 
are involved in the hematopoietic differentiation. The capacity to silence those 
genes depends on its capacity to bind DNA, recruit chromatin modifiers 
(histone deacetylase (HDACs) and DNA/histone methyltransferases) and 
induce changes in chromatin structure that are not permissive for transcription 
(Grignani et al., 1998; Lin et al., 1998; Minucci et al., 2001). Recently, it has 
been shown that the PML-RARα inhibits p53 by a mechanism independent 
from its transcriptional properties. The PML-RARα associates with p53, 
deacetylates later by recruiting HDACs and subsequently degrades p53 via the 
proteasome/MDM2 pathway in hematopoietic precursor cells (Insinga et al., 
2005). Furthermore, PML-RARα physically interacts with PML, disrupts the 
PML nuclear bodies (NB) in a dominant negative manner. This induces the 
delocalisation of PML as well as the other NB component into an aberrant 
nuclear subdomains, thus potentially impairing PML function (Koken et al., 
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1994; Zhong et al., 2000). PML-RARα does not rely only on its ability to 
affect myeloid differentiation. Recent studies shows that the transgenic 
animals expressing the PML-RARα fusion protein have a myeloproliferative 
syndrome with elevated numbers of myeloid cells in the marrow and the 
spleen (Kelly et al., 2002). This suggests that the PML-RARα fusion protein 
leads to an increased proliferative rate of the leukemic cells. Additionally, It 
has also been reported from PML-RARα transgenic mice that the leukemic 
cells actively proliferate and can form an increased number of colonies in in-
vitro bone marrow cultures (He et al., 1998). These data would suggest an 
indirect role of PML-RARα in cell cycle. However this has not been 
investigated so far. In fact, a dominant negative action of PML-RARα on 
PML could result in shortening of the transition through the cell cycle 
(Pandolfi PP, 2001). Pml-/- cells have an increased proliferative potential in 
view of faster transition through the G1 phase of the cell cycle (Wang et al., 
1998a). 
A limited number of APL cases have been described with alternative 
chromosomal translocations, like the t(11;17) which generates a distinct 
fusion gene PLZF-RARα, the t(11;17) which gives rise to NuMA-RARα
fusion gene and the t(5;17) that gives rise to the NPM-RARα fusion gene  as 
depicted in Figure 3 (Corey et al., 1994; Licht et al., 1995; Look, 1997; 
Redner et al., 1996).
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RARα(17q21)PML(15q22)
(Promyelocytic Leukemia)
PLZF (11q23)
(Promyelocytic Leukemian
Zinc Finger)
NPM (5q35)
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Figure 3: Graphical representation of N (PML, PLZF, NPM, and NuMA), RAR  and 
N/RAR  (PML-RARα) fusion protein. The four chromosomal translocations associated 
with APL results in fusion proteins in which the B through F domains of RARα, including 
the DNA binding and ligand binding domains of proteins, are linked C-terminal to four 
different nuclear proteins containing self-association domain. The t(11;7) APL syndrome 
linking PLZF and  RARα is unique among these forms of APL in its resistance to 
differentiation therapy with ATRA or conventional chemotherapy(A = Transcriptional 
Activation AF-1, B = Transcriptional Activation AF-1, C = DNA Binding (RARE) Zn 
Fingers, D = Hinge Region, E = Ligand Binding Hetrodimerization  Transcriptional 
Activation AF-2, N-Cor/SMRT Binding, TIF-1/TIF-2/CBP Associate and F = Function 
Unknown) (Melnick and Licht, 1999).
1.3 The effect of ATRA in APL and its role in the degradation of PML-
RARα
APL is the first human malignancy that can be efficiently treated with a cell 
differentiation inducer All-Trans-Retinoic Acid (ATRA) and chemotherapy in 
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both remission induction and maintenance therapy (Douer, 2002). Treatment 
of APL with ATRA leads to complete remission (CR) in about 90% of 
patients, which is attributable to proteolysis of PML-RARα, re-formation of 
PML-NB, and terminal differentiation of APL cells into normal granulocytes 
(Breitman et al., 1981; Chambon, 1996). Restored PML protein and RARα
overcomes the differentiation block and causes commitment of APL cells into 
granulocyte differentiation (Grignani et al., 1993a; Grignani et al., 1993b; 
Yoshida et al., 1996).  In addition to the release of transcriptional repression 
with pharmacological ATRA level (10
-6
-10
-7
M), other possible mechanisms 
involved in ATRAs effectiveness in myeloid cell differentiation include 
expression of different gene classes, including induction of p21, cyclin-
dependent kinase inhibitor, C/EBP-α, β, and ε, interferon regulatory factor 1 
(IRF-1); and the regulation of localization of PML oncogenic domains (PODs) 
(Weis et al., 1994).
The success of retinoic acid (RA) as a standard therapy for the 
induction of remissions in patients with APL led to the notion that a defect in 
the RA signaling pathway could be responsible for the differentiation block in 
APL (Zhong et al., 2000). A report by Kastner et al. (Wang et al., 1998b)
indicated that disruption in the RA signaling pathway is not sufficient to 
provide an explanation for the differentiation block since granulocytic lineage 
commitment is not impaired in RARα and RARγ-deficient mice. The global 
analysis of multiple gene expression patterns using cDNA microarray 
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technologies has provided additional information at the transcriptional level in 
response to ATRA- induced cell differentiation (Lee et al., 2002; Liu et al., 
2000; Yang et al., 2003).  These studies have established the gene networks in 
the NB4 cells that define phenotypic changes during decrease in cellular 
proliferation and promotion of granulocytic maturation by up-regulation of 
p19, GADD153, BTG1 and  src-like adaptor (Liu et al., 2000).
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Figure 4: Model of transcription repression in the pathogenesis and hormonal 
response of APL. Under physiological concentrations of RA, the expression of RA target 
genes is repressed by X-RARα proteins through the action of the corepressor-HDAC 
complex. This results in the block of myeloid differentiation. Under pharmacological doses 
of RA, PML-RARα but not PLZF-RARα, dissociates the corepressor-HDAC complex and 
activates differentiation target genes and induces clinical remission in APL patients. The 
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combination of RA and HDAC inhibitors may be able to overcome RA resistance and 
trigger remission in PLZF-RARα-positive APL as indicated by a dashed line (Lin et al., 
2001).
1.4 Proteomics and its role in understanding the biology and the    
mechanism of a diseased state
The array of proteins found within the cell, their interactions and 
modifications hold the key to understand the biological systems. This is 
encapsulated in the term “Proteome”. It can be defined as the total sum of 
protein of a cell, characterized in terms of localization, posttranslational 
modifications (PTM), interaction, and turnover, at any given time. 
Before the advent of advanced mass spectrometry and proteomic 
technology, DNA microarray analysis was applied to identify molecular 
markers of human haematological malignancies. This technology readily 
allows measurement of the expression levels of thousands of genes 
simultaneously (Duggan et al., 1999). Expression profiling with microarrays 
has thus, made it possible, for example, to distinguish acute myeloid leukemia 
(AML) from acute lymphoid leukemia (ALL) (Golub et al., 1999), to define 
novel subgroups of leukemias and lymphomas (Alizadeh and Staudt, 2000; 
Armstrong et al., 2002), and to identify candidate genes leading to 
leukemogenesis (Makishima et al., 2002; Ohmine et al., 2001). Despite its 
potential for identifying genes important in leukemogenesis, microarry 
analysis is not able to provide direct information of proteins. Furthermore the 
transcriptional activity of a given gene is not always a major determinant of 
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the expression level of the translated protein. The characterization of 
leukemogenesis thus, requires a direct determination of the accompanying 
changes not only in the amount of cellular mRNAs but also in the protein 
abundance. The activities of many proteins are influenced by posttranslational 
modifications, such as phosphorylation, glycosylation, ubiqitination and 
sumoylation, which can only be assessed by MS based proteomics. Since the 
introduction of the term “proteomics” in 1995 (Wasinger et al., 1995), the 
proteomic analysis has gained considerable interest and is presently being 
used as a major tool for profiling proteins and biomarker for drug-discovery 
(Larsen et al., 2001).
The acute promyelocytic leukemia (APL) model system has turned out 
to be a useful tool to identify molecular pathways that could be manipulated 
for cancer therapy. Post-genomic strategies are being applied to identify genes 
and their encoded proteins that function in disease progression. A large 
amount of gene expression data and retinoic acid-responsive genes are 
available for APL (Walter et al., 2004). However, the need for protein 
expression data becomes inevitable. Therefore, global high-throughout 
functional proteomics could lead to new insight into the network of protein-
protein interactions and target proteins involved in leukemia as well as 
provide new targets for pathogenesis based therapies of leukemia.
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1.5 Cell cycle and its role in leukemogenesis 
All cells reproduce by performing an orderly sequence of events in the cell 
cycle phase and duplicate its contents and then divide into two. Upon 
activation of mitogenic signalling cascades, cells commit to entry into a series 
of four sequential steps allowing traverse of the cell cycle: G1 (first gap), S 
(synthetic phase), G2 (second gap), and M (mitosis). Synthesis of DNA 
(genome duplication), also known as S phase, is followed by separation into 
two daughter cells (chromatid separation or M phase). During the G2 phase 
(the time between the S and M phases) cells can repair errors that occur during 
DNA duplication, preventing the propagation of these errors to daughter cells. 
In contrast, the G1 phase the time between the M and S phase represents the 
period of commitment to cell cycle progression. In order for the cell to 
continue cycling to the next phase, the prior phase has to be properly 
completed; otherwise, “fail safe” mechanisms, also known as “cell cycle 
checkpoints”, are elicited (Paulovich et al., 1997). The cell cycle machinery is 
controlled by the sequential activation of genetic programs including the 
synthesis of cyclins, the activation of the cyclin-dependent kinases (CDK) and 
cofactors, including cyclins and cdk inhibitors (CDKIs). The main function of 
the CDKs is the phosphorylation of substrates required for the cell cycle 
progression (Morgan, 1997; Muchardt and Yaniv, 2001).  
Cell cycle regulation plays an important role for cell growth and 
differentiation. During hematopoiesis, cell cycle control genes are 
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distinctively regulated in a lineage dependent manner, reflecting the cell cycle 
characteristics of each lineage (Dao and Nolta, 1999; Furukawa, 1998; 
Steinman, 2002). Alterations in cell cycle machinery, especially in the G1/S 
phase regulation are known to be linked to the development of solid tumours 
as well as hematological malignant diseases (Hangaishi et al., 1996; Ogawa et 
al., 1994). For example, overexpression and prognostic significance for cyclin 
E has been reported in chronic lymphocytic leukemias and lymphomas 
(Erlanson et al., 1998; Wolowiec et al., 1995), overexpression of cyclin E has 
been observed in AML (Iida et al., 1997; Radosevic et al., 2001) and 
expression of p27 protein is significantly correlated with the response to 
chemotherapy (Radosevic et al., 2001). The role of cyclin A in development 
of AML has been demonstrated in transgenic mice, in which a targeted 
overexpression of the cyclin A1 in early myeloid cells initiated AML (Liao et
al., 2001).
1.6 Microtubule dynamics during the cell cycle 
When a cell divides into two daughter cells, the chromosomes must segregate 
prior to cell division. This process is mediated by a complex structure, the 
mitotic spindle, which is composed of microtubule polymers consisting of α/β
tubulin heterodimers (Desai and Mitchison, 1997). The movement of 
chromosomes on the mitotic spindle is dependent on the dynamic instability 
of microtubules, a characteristic property of microtubles that allows them to 
switch abruptly between the state of elongation and rapid shortening (Desai 
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and Mitchison, 1997). The transition frequencies from a state of growth to a 
state of shortening is called ‘catastrophe’ and from a state of shortening to 
growth is called ‘rescue’ (Desai and Mitchison, 1997). The dynamics of 
microtubule polymerization and depolymerization during the cell cycle are 
regulated by a balance between the activities of two major classes of proteins, 
the microtubule-stabilizing microtubule-associated proteins (MAPs), which 
stabilize the assembled microtubules by suppressing catastrophe (Cassimeris, 
1999), and destabilizing the protein OP18 (Belmont and Mitchison, 1996), the 
KinI family of kinesin-related protein (XKCM1 and XKIF2) (Desai and 
Hyman, 1999) , and the microtubule severing proteins (Katanin, p56 and 
EF1a) (McNally and Vale, 1993; Shiina et al., 1994). OP18 has been shown to 
stimulate transition from elongation to shortening of MTs (Walczak, 2000). 
1.7 OP18 
OP18 is a highly conserved 19kDa cytopalsmic and soluble phospho-protein, 
also designated as Stathmin, p19, prosolin, p18 or OP18, oncoprotein18 and 
pp20-pp21-pp23 (Cooper et al., 1991; Luo et al., 1991; Marklund et al., 1993; 
Peyron et al., 1989; Schubart et al., 1992). The OP18 family contains 
phosphorylation-controlled MT destabilizing proteins that are important for 
proper cell cycle progression in many types of proliferating eucaryotic cells 
(Andersen, 2000; Cassimeris, 2002; Gavet et al., 1998; Lawler, 1998; Sobel, 
1991), crucial for the development of the nervous system in drosophila (Ozon 
et al., 2002) and are implicated in a wide variety of cancers (Bieche et al., 
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1998; Melhem et al., 1997). The monomeric OP18 protein consists of an N-
terminal capping domain (Steinmetz et al., 2000) and a C-terminal helical 
interaction domain (Belmont et al., 1996).  The N-terminal region of OP18 is 
required for catastrophe-promotion while the C-terminal region is required to 
inhibit the MT-polymerization rate in-vitro (Holmfeldt et al., 2001). 
Originally, OP18 was described as a protein that binds to tubulin dimers 
and increases the catastrophe frequency of MT in-vitro. Subsequent studies  
identified two putative mechanisms for OP18: (i) tubulin dimer sequestration 
that slows  the MT growth rate (Curmi et al., 1997; Jourdain et al., 1997) and 
(ii) direct stimulation of MT plus-end catastrophes as depicted in Figure 5
(Arnal et al., 2000; Holmfeldt et al., 2001; Howell et al., 1999; Larsson et al., 
1999; Segerman et al., 2003; Tournebize et al., 1997). Besides microtubule 
depolymerization activity, OP18 is regulated by changes in its level of 
phosphorylation that occur during cell cycle progression as depicted in Figure 
6 (Mistry and Atweh, 2002). OP18 is phosphorylated in multiple and complex 
ways in response to a variety of extra cellular stimuli on four Serines (S16, 
S25, S38, and S63) (Amat et al., 1991; Curmi et al., 1999; Doye et al., 1990; 
Sobel et al., 1989). Phosphorylation of OP18 is regulated by cyclin dependent 
kinases (CDKs).
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1.8 Role of OP18 in the regulation of cell cycle, microtubule dynamics and 
mitotic phase of the cell cycle
The first hint that OP18 may play a role in the regulation of cell cycle 
progression came from the observation that the level of phosphorylation of 
OP18 increases when erythroleukemic K562 cells enter the mitotic phase of 
the cell cycle (Luo et al., 1994). The level of OP18 phosphorylation is 
significantly lower in cells blocked in the G1/S phases of the cell cycle 
compared to proliferating cells and peaks in mitosis in both jurkat T cell and 
HeLa cells (Brattsand et al., 1994). The fact that both overexpression 
(Marklund et al., 1994a) and inhibition of OP18 expression (Luo et al., 1994)
result in mitotic arrest generated a paradox that was resolved by the 
independent identification of OP18 as a cellular factor involved in the 
regulation of microtubule dynamics (Belmont and Mitchison, 1996). Belmont 
and Mitchison proposed the first model to explain the mechanism by which 
OP18 exerts its mitotic effect through an increase in the rate of catastrophe. 
Subsequently, a different model was proposed by Jourdain et al (Jourdain et 
al., 1997) in which the microtubule-depolymerizing activity of OP18 is 
mediated through direct sequestration of tubulin. This model is based on the 
observation that OP18 binds two unpolymerized tubulin heterodimers and 
forms a ternary OP18-tubulin complex (T2S). In conclusion, these studies 
demonstrate that OP18 is capable of binding both polymerized and 
unpolymerized tubulin and can prevent polymerization of α/β heterodimers 
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under some conditions and/or promote depolymerization of microtubules 
under others. 
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Figure 5: Models for OP18 induced destabilization of microtubules. (a) The dynamic 
instability of microtubules. (b) Tubulin sequestering activity of OP18. (c)  The dual activity 
of OP18 (Mistry and Atweh, 2002).
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Although the exact molecular mechanisms by which OP18 exerts its 
mitotic function are still unknown, there is wide consensus that its 
microtubule-depolymerizing activity is essential for orderly progression 
through the cell cycle. As cells proceed through anaphase and telophase, 
fluctuations between microtubule polymerization and depolymerization lead 
to the structural reorganization and eventually the disassembly of the spindle, 
which is followed by the exit from mitosis and cytokinesis. Microtubules then 
reorganize into a new interphase cytoskeleton upon entry into a new cell cycle 
(Rubin and Atweh, 2004). Fig 6 depicts a schematic representation of role of 
OP18 during cell cycle progression. 
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Figure 6: Regulation of OP18 activity during cell cycle progression. The 
unphosphorylated form of OP18 in late interphase promotes depolymerization of 
microtubules, and phosphorylation of stathmin early in mitosis turns off its activity, 
allowing the mitotic spindle to form. Dephosphorylation of OP18  during late mitosis is 
necessary for spindle disassembly and exit from mitosis (Mistry and Atweh, 2002).
1.9 Role of OP18 in cell proliferation
A growing set of arguments indicate that OP18 may participate in the control 
of cell proliferation. Data from development, tissue regeneration, cell biology 
or cancer studies indicate that there are differences in expression patterns of 
OP18 (Doye et al., 1992; Koppel et al., 1990; Koppel et al., 1993). For 
example, during development OP18 expression is high in undifferentiated 
multipotent cells of the early embryo (Doye et al., 1990) and  in most tissues 
at the neonatal period (Doye et al., 1989; Schubart et al., 1992). In addition it 
is strongly decreased in the adult, remaining abundant mostly in the nervous 
system and in the testis (Koppel et al., 1990; Peschanski et al., 1993). 
Moreover, studies in several leukemic cell lines and in primary acute leukemia 
cells showed that OP18 expression is drastically decreased when the cells 
decrease to proliferate upon exposure to a variety of differentiation agents 
(Chen et al., 2003; Feuerstein and Cooper, 1983; Hanash et al., 1988; Luo et 
al., 1991). Furthermore, OP18 expression was markedly increased when 
normal lymphocytes are induced to proliferate by exposure to mitogenic 
stimuli (Hanash et al., 1988). Interestingly, the level of OP18 expression in 
leukocytes from patients with chronic myelogenous leukemia was also shown 
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to increase significantly when the disease progresses in to the more 
proliferative stage known as “blast crisis” (Rubin and Atweh, 2004). A similar 
observation was made in undifferentiated multipotential embryonal carcinoma 
cell lines where OP18 expression was decreased upon induction of 
differentiation. Besides, in other solid tumours like breast and ovarian cancer, 
it was shown that poorly differentiated tumours with a high proliferative 
potential expressed higher levels of OP18 than more differentiated and less 
proliferative tumours (Brattsand, 2000). All these observation suggested a 
strong correlation between OP18 expression and cellular proliferation in both 
normal and malignant cell.
1.10 Aim of this study
The PML-RARα fusion protein has the potential to inhibit terminal 
differentiation of hematopoietic precursor cells thereby giving leukemic blast 
a proliferative and survival advantage. However, the precise mechanism by 
which the PML-RARα fusion protein causes an APL phenotype remains 
largely unknown. Recent developments in the proteomics technology and 
mass spectrometry enabled us to address this question and analyze the 
changes in global protein expression induced by the fusion protein PML-
RARα.
The objective of the present study is to identify differentially regulated 
proteins of PML-RARα, the posttranslational modification of the proteins and 
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the biological characterization of identified proteins by applying proteomic 
technology (2D gel electrophoresis and mass spectrometry).
2. Materials and Methods 
2.1 Materials
2.1.1 Mammalian cell line
NB4 a maturation inducible cell line with t(15;17) marker (from DSMZ Acc 
207)
U937 (Human myeloid cell line, monoblastic)
P/R-U937 cells (PML-RARα stably transfected U937 zinc inducible cells), 
kindly provided by Dr. Pellici
Cells from APL patients (bone marrow), kindly provided by Leukemia 
Diagnostic Laboratory, Medicine III Klinikum Großhadern, Munich.
2.1.2 Antibody  
Anti- β-tubulin (Boehringer Mannheim, Germany)
Anti-Cdk2 (Santa Cruz Biotechnology, CA, USA, sc-163)
Anti- Cdk4 (Santa Cruz Biotechnology, CA, USA, sc-260)
Anti-GRP75 (Santa Cruz Biotechnology, CA, USA, sc-13967) 
Anti- HSP70 (Santa Cruz Biotechnology, CA, USA, sc-7298) 
Anti-MPM2 (Upstate Biotechnology, CA, USA, 05-368)
Anti- OP18 (Santa Cruz Biotechnology, CA, USA, sc-20796)
Anti- Pin1 (Santa Cruz Biotechnology, CA, USA, sc-15340)
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Anti- p21 (Santa Cruz Biotechnology, CA, USA, sc-817)
Anti- PP2A (Santa Cruz Biotechnology, CA, USA, sc-14020)
Anti- PP2BA (Santa Cruz Biotechnology, CA, USA, sc-9070)
Anti-pOP18 (Santa Cruz Biotechnology, CA, USA, sc-12949-R) 
Anti-RARα (Santa Cruz Biotechnology, CA, USA, sc-551)
2.1.3 Mutagenesis 
Effectene transfection reagent (Qiagen, Germany)
GFP (Invitrogen, Germany)
Nucleofector kit (AMAXA, Cologne, Germany)
PCEP4-Op18 plasmid (from Dr.Samir Hanash)
Site-directed PCR Mutagenesis kit (Stratagene)
Primers (forward/reverse) for the generation of OP18 (NM_203401)
Ser63/ala (phosphorylation deficient mutant) and Ser63/asp (constitutive
active mutant) (Metabion)
2.1.4 Chemicals 
Acetonitrile (Sigma Aldirch, USA)
Acetic acid (Merck, Darmstadt, Germany)
Ammonium bicarbonate (Sigma, USA)
Dimethyl sulfoxide (DMSO) (Sigma, USA)
Ethanol (Merck, Darmstadt, Germany)
Formaldehyde (Merck, Darmstadt, Germany)
Glycine (ICN Bio-medicals)
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Isopropanol (Merck, Darmsadt, Germany)
Methanol (Merck, Darmstadt, Germany)
Propidium iodide (Sigma, USA)
Silver nitrate (Merck, Darmsadt, Germany)
Sodium carbonate ( Merck, Darmstadt, Germany)
Sodium thiosulfate (Merck, Darmstadt, Germany)
Sodium dodecyl sulphate (SDS) (Sigma, USA)
Trifluoroacetic acid (TFA) (Merck)
Triton X-100 (Sigma, USA)
Zinc sulphate (Sigma, USA)
2.2 Methods
2.2.1 Immunoblot analysis
Total cellular protein was extracted from PR9 cells and U937 cells before and 
after 100µM Zinc sulphate treatment using RIPA laysis buffer (50mM Tris pH 
8.0, 150mM NaCl, 1% Nonidet p-40 (Np40), 0.5% sodium Deoxycholate, 
0.1% SDS, 5mM EDTA, Phosphatase and proteinase inhibitors cocktail). 
Protein concentration was measured using BioRad protein assay reagent. 
Equal amount of protein were mixed with equal amount of 2X loading dye 
(0.5M tris pH 6.8, 10% SDS, 100% glycerol, 2-mercapto ethanol, pinch of 
bromophenol blue and dH2O) and boiled to 95
o
C for 5 minutes. The sample 
was cooled on ice, centrifuged briefly and subjected to electrophoresis on 10% 
SDS-PAGE gels and transferred into Immobilin-P transfer membrane 
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(Millipore, Massachusetts, and USA). The western blotting procedure was 
performed and the blots detected with the ECL system as described previously 
(Behre et al., 1999b). Immunoblot analysis was performed for RARα, OP18, 
HSP70, GRP75, Pin1, CDk2, CDk4, PP2A and PP2BA. Anti-β-tubulin  and 
annti-γ-tubulin antibody (Boehringer Mannheim, Germany) was used as 
internal loading control on the same blot after stripping.
2.2.2 Quantitative two-dimensional gel electrophoresis 
PR9 cells were induced for PML-RARα with 100 µM Zinc sulphate for 6h. 
The whole cell lysates were then prepared using urea laysis buffer (9.8M urea, 
1% DTE, 4% CHAPS, 2.5mM EDTA and 2.5mM EGTA) and the total 
protein concentration determined by BioRad-assay as described previously 
(Zada et al., 2003). The isoelectric focusing was performed with 1 mg (for 
coomassie stained gel) or 300µg (for silver stained gel) of protein (total 
volume was 360µl, mixed with 2.25µl of resolyte and 2µl of 0.5% 
bromophenol-blue) samples by using immobilized pH gradient (IPG) strips 
pH 3-10 and pH 4-7 (Amersham).  The IPG strips were incubated for 10 min 
with DTE and carbamylation buffer respectively, washed two times with 
ddH2O and subjected to second dimension. The proteins were then separated 
in the second dimension by 12% SDS-PAGE and protein spots visualized by 
either colloidal coomassie blue staining or silver staining. 2D-DIGE was also 
performed with 50µg of protein using fluorescent dyes.
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2.2.3 Data analysis by ProteomeWeaver
The gels were scanned as 16 bit images (UMAX , PowerLook 2100XL 
scanner) and analyzed with the ProteomWeaver software version 2.1 
(Definiens, Munich, Germany). The protein pattern of three independent gels 
(both uninduced and induced conditions) was used to generate an average gel 
and the spots detected in comparison with one another in terms of their 
intensity on the gels. The pair match-based normalization function of the 
program enabled us to remove nonexpression related variations in the spot 
intensity. With the support of statistical analysis, we could detect and analyze 
differentially regulated proteins in induced condition as compared to 
uninduced condition. 
2.2.4 Mass spectrometry
The spots were carefully excised from the gels with a pipette tip, 3 times 
washed with dH2O for 15 minute each. The spot were incubated with 50% 
Acetonitrile and 50mM Ammonium bicarbonate (NH4HCO3) and repeated 
two times. Trypsin enzyme (5ng/µl) reconstituted with ammonium 
bicarbonate (NH4HCO3) was used for overnight digestion at 37°C. The tryptic 
peptides were extracted in 70% acetronitrile. The supernatant were dried using 
speedVac (SPD111V, Savant) and resuspended in 20% acetronitrile, 0.1% 
TFA and sonicated for 3 minutes before processing for mass spectrometry. 
The extracted peptides (0.6 µL) were loaded onto the anchor chip target plate 
by mixing the peptides with the matrix in a ratio of 1:1. We used DHB matrix, 
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which is prepared by mixing 20 mg/ml 2.5-dihydroxy-benzoic acid with 20 
mg/ml 2-hydroxy-5-methoxy-benzoic acid (9:1 v/v respectively) and used for 
our analysis. Measurements were performed using a ReflexIII MALDI-TOF 
instrument (Bruker Daltonic, Germany), operated in reflector mode, with an 
accelerating voltage of 20 kV. The identification of the proteins proposed by 
PMF from MALDI-TOF analysis and differentially regulated by PML-RARα
was also confirmed by using MS/MS with AB4700 GPS explorer Software 
(Applied Biosystems). We used CHCA matrix For MS MS analysis, which is 
prepared by mixing 8mg of CHCA (Sigma) in 200µl solvent solution 
(50%Acetonitrile and 0.05% TFA). 2/3 of solvent solution mixed in to 1/3 of 
CHCA solution and 0.5µl matrix and 0.5µl of sample were loaded on the plate 
and dried. After drying the analysis was performed. Peptide masses were 
searched against Mascot database (Matrix Science). 
2.2.5 Gene expression profiles of clinical samples
Microarray analyses were performed with bone marrow sample of acute 
myeloid leukemia patients utilizing the U133A microarrays GeneChip 
System
®
 (Affymetrix U95 Av2 and U133A Santa Clara, CA, USA). Target 
cRNA preparation from total RNA, hybridization to the microarray, washing 
and staining with the antibody amplification procedure, and scanning were all 
carried out according to the manufacturer’s instruction on analysis technical 
manual as described previously (Schoch, Kohlmann et al., 2002). To compare 
different experiments, the global microarray intensities were scaled to 
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common target intensity. Each new human GenChip expression array features, 
100 human maintenance gene that serve as a tool to normalize and scale the 
data before performing data comparisons. These 100 probe sets were used for 
normalization, as recommended by the manufacturer (U133A mask file. 
http://www.affymetrix.com\suport\technical\mask_filesaffx.). Scaling was 
performed to a target intensity of 5000. All probe sets representing genes of 
interest were functionally annotated by NetAffx database (affymetrix), and 
HGNC (HUGO Gene Nomenclature Committee) approved gene symbols were 
proven.
2.2.6 Transient transfections and reporter assays
Transfections in 293T cells were carried out with Lipofectamine (Invitrogen). 
The luciferase reporter construct for OP18 used was a kind gift from Dr. 
Herrera: pOP18-luc. Other expression plasmids used are: pSG5-PML-
RARα, pSG5-RARαand pCDNA3-PML. Transient transfections were carried 
out with promoter/luciferase construct and cotransfected with expression 
plasmids for human PML-RARα, RARαPML and Renilla Luciferase-null. 
Promoter activities were determined by measuring the luciferase activity with 
the Dual Luciferase Assay System (Promega). Firefly Luciferase activities 
were normalized to the Renilla Luciferase values of pRL-0.
2.2.7 Immunofluorescence
PR9 cells (3x10
5
) under uninduced or induced for PML-RARα conditions 
were cytocentrifuged on glass slides with coverslips, fixed using 1:1 
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methanol/acetone and permeabilized using 0.3% TritonX. After blocking in 
PBG (0.5% BSA, 0.045% Fish-gelatin in PBS) containing 5% FBS, the fixed 
cells were incubated with anti-OP18 (anti-rabbit sc-20796, Santa Cruz) and 
anti-α−tubulin (anti-mouse) antibodies followed by incubation with Alexa 
Fluor 488 chicken anti-rabbit and Alexa Fluor 594 chicken anti-mouse IgG 
secondary antibodies (Molecular Probes) respectively and 4´, 6´-diamidino-2-
phenylindole dihydrochloride (DAPI, 1µg/ml) for 15 min. The cells were 
mounted in aqueous mounting medium and the images were acquired and 
analysed using a fluorescence microscope.
2.2.8 Cell cycle and mitotic index evaluation
We used propidium iodide (PI) staining to analyze the distribution of cells in 
the different phases of the cell cycle as described previously (Zada et al., 
2003). Briefly, PR9 cells and U937 cells (5x10
5
) under uninduced or induced 
for PML-RARα conditions were washed once in PBS 1X 1000RPM for 10 
minutes at 4
0
C. The cells were resuspended with 200µl PI lysis buffer (0.1% 
Sodium citrate, 0.1% Triton X -100, and 20µg/ml Propidium Iodide). The 
lysate were incubated on ice for 5 minutes and FACS analysis was done using 
the ModFit LT
TM
 3.0 software (Becton Dickinson). Standard statistical 
methods were used to analyse the cell cycle data including mean, standard 
deviation and standard error of the mean. P value was calculated from the 
student`s t-test by comparing the means of two different conditions in each 
experiments. For mitotic index, the cells under different conditions were 
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cytocentrifuged onto glass slides, fixed in methanol and then stained with 
either DAPI or Wright-Giemsa for 10 min. The mitotic cells were counted in 
different fields and represented as a percentage of total cells (mitotic index 
MI). 150-200 cells were counted for quantification.
2.2.9 In- vitro kinase assay
PR9 cells were washed with cold PBS and RIPA lysates prepared at different 
time points. Lysates were collected by centrifugation for 30 min and protein 
concentrations were quantified by the Bradford assay (Bio-Rad Laboratories, 
Germany). 200 µg of protein was incubated with 2 µg of anti-CDK2 or anti-
CDK4 antibody at 4° C for 2 h with rotation. Protein A agarose beads (20 µl) 
was then added and the incubation continued for another 2 h. Immunocomplex 
beads were washed twice with PBS buffer and three times with kinase buffer 
(150 mM NaCl; 1 mM EDTA; 50 mM Tris-HCl, pH 7.5; 10 mM MgCl2; and 
10 mM DTT). Kinase activity was assayed by incubating the beads at 37° C 
for 30 min with 25 µl kinase buffer, 3 µg histone H1 (Upstate, Germany; 
CDK2) or Rb-fusion protein (Santa Cruz; CDK4), 10 µM ATP, and 4 µCi [γ-
32P] ATP (3000 Ci/mmol). Samples were then boiled for 5 min in 2 times 
sample buffer electrophoreses through a 12% SDS-polyacrylamide gel, dried, 
and phosphorylated histone H1 and Rb proteins were visualized by auto 
radiography. Also shown is an immunoblot IP control for CDK2 and CDK4.
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2.2.10 RNA interference using siRNA 
For knocking-down OP18 expression in PR9 cells, we used siRNA 
technology. The targeted sequence of OP18 was empirically determined in the 
OP18 coding sequence and was verified by BLAST searches. To ensure gene 
(or protein) specific effects, we designed 2 oligos corresponding to DNA 
target sequences CTG CCT GTC GCT TGT CTT CTA and TTG AGT TAG 
GTT AAT AAA TCA of the OP18 sequence (gene accession number 
NM_203401): oligo1, sense r (GCC UGU CGC UUG UCU UCU A) dTdT 
and antisense r (UAG AAG ACA AGC GAC AGG C) dAdA; oligo2, sense r 
(GAG UUA GGU UAA UAA AUC A) dTdT and antisense r (UGA UUU 
AUU AAC CUA ACU C) dAdA. The oligos were transfected into PR9 and 
U937 cells using RNAiFect essentially using manufacturer’s instructions with 
minor modifications (Qiagen). A random DNA target sequence AAT TCT 
CCG AAC GTG TCA CGT with the siRNA duplex sequences, sense r (UUC 
UCC GAA CGU GUC ACG U) dTdT and antisense r (ACG UGA CAC GUU 
CGG AGA A) dAdA was used as a non-silencing siRNA control and siRNA 
conjugated to rhodamine was also used to visualize the transfection efficiency 
of the transfected siRNA sequences into the cells. For the transfection of 
siRNA into cells, RNAiFect (Qiagen) was used. 5-10 µg of each siRNA was 
used in each condition; the cells were analyzed for toxicity 18-24h post-
transfection and then stimulated further with RA or Zn when needed. The 
effect of siRNA on protein expression of OP18 was analyzed by immunoblot.
32
2.2.11 Construction of OP18 mutants and transfections
The pCEP4-OP18 plasmid was a kind gift from Dr. Samir Hanash. PCR 
mutagenesis kit (Stratagene) was used for the generation of OP18 mutants 
from this plasmid. The primers used for the generation of OP18 Ser63/ala 
mutant were, forward 5`-GAA AGA CGC AAG GCC CAT GAA GCT GAG-
3` and reverse 5`-CTC AGC TTC ATG GGC CTT GCG TCT TTC-3`and for 
OP18 Ser63/asp mutant were, forward 5`-GAA AGA CGC AAG GAC CAT 
GAA GCT GAG-3` and reverse 5`-CTC AGC TTC ATG GTC CTT GCG 
TCT TTC-3`. All the plasmid constructs were verified by sequencing. It is 
important to mention here that Serine/threonine-to alanine substitution has 
been shown to block phosphorylation in a number of proteins. On the other 
hand, conversion of the Serine/threonine to aspartic acid mimics 
phosphorylation of these residues since, aspartic acid has a negative charge 
and is enough to maintain the phosphorylation status of the protein (Hall et al., 
1996; Huang and Erikson, 1994; Warnock et al., 2005). For the transfection of 
PR9, U937 and NB4 cells, effectene transfection reagent were used (Qiagen). 
For the transfection of APL patient samples, cell nucleofector kit (AMAXA) 
was used essentially as described by manufacturer. 5µg of plasmid DNA 
constructs were used for each transfection and the analysis (3x10
5
) was 
performed 14h later. For analyzing transfection efficiency, a plasmid with 
GFP marker (2µg) was used.
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3. Results
3.1 The PML-RARα fusion protein is induced after the addition of zinc in 
PR9 cells
In the present study, we used an in-vitro cell line model system, the PR9 cells, 
kindly provided by Dr. Pellici, which has PML-RARα cDNA under the 
control of the Zinc inducible metallothionein promoter. PR9 and U937 cells 
were induced with 100µM zinc sulphate at different time point. Expression of 
the PML-RARα fusion protein in PR9 cells (Fig. 7a) could be detected after 
zinc induction, which persisted till 12 h and then gradually decreased 
thereafter. However, expression of the fusion protein was maintained by 
continual addition of zinc to the medium after every 12 h time period of 
induction (data not shown). U937 cells under similar condition were used as a 
zinc control (Fig. 7b). The expression level of PML-RARα (Fig. 7a) has 
previously been shown to be comparable to those of APL blasts (Casini and 
Pelicci, 1999).
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Figure 7: PML-RAR  is induced after zinc induction in PR9 cells: (a) Immunoblot 
analysis showing the expression of PML-RAR  in PR9 cells upon Zinc induction (100µM 
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ZnSO4) using anti-RAR  antibody (C-20, sc-551 Santa Cruz). (b) U937 cell were used as 
zinc control.
3.2 PML-
protein expression: two-dimensional gel analysis approach 
No systematic identification and characterization of the global proteome and 
the corresponding cellular function of the PML-RARα fusion protein has been 
reported till date. To this end, we used a global proteomic approach to identify 
target proteins of the fusion protein in an in vitro cell line model system. 
Proteins from PR9 cells induced for PML-RARα (with treatment with ZnSO4
for 6h) were separated using a pH 3-10 and a pH 4-7 immobilized pH gradient 
gel in the first dimension followed by SDS-PAGE. The 2D gels were stained 
with either colloidal coomassie blue (Fig. 8a) or silver (Fig. 8b) to obtain a 
spot pattern under each condition (without and with PML-RARα). The spot 
patterns were quantitatively analyzed by the ProteomWeaver software, which 
generated nonwarped and warped images corresponding to each gel, under 
uninduced (without PML-RARα) and induced (with PML-RARα) condition 
(Fig.8d). This allowed us to individually look for the differences in the protein 
expression corresponding to each spot in a single gel. The spot patterns were 
observed to be reproducible and the degree of reproducibility shown as a 
scatter plot between a reference gel and the two other gels (Fig. 8f) with 
correlation coefficients of 0.58 and 0.66, statistically calculated by the 
software.
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Of the total of 224 proteins identified, PML-RARα in PR9 cells showed 
significant changes in 47 proteins that exhibited a 1.5-fold change or greater, 
of which the expression of 25 proteins was found to be increased and the 
expression of 22 proteins decreased upon PML-RARα induction (Table 2) 
compared to the uninduced control. As an illustration of changes occurring in 
the protein expression as a consequence of PML-RARα induction, we have 
compared changes without and with PML-RARα (Fig. 8c). To rule out the 
changes in protein expression as a result of zinc induction, we used the 
parental U937 cells as control (Fig. 8a bottom panel). In addition to coomassie 
and silver staining procedures, we also performed a more reliable quantitative 
fluorescent 2D DIGE staining methods using Cy3 and Cy5 labelling dyes 
(Amersham, Germany) in PR9 cells under uninduced and induced conditions 
(data not shown). 
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Figure 8: 2D gel electrophoresis showing PML-RARα regulated proteins. The 2D gel 
electrophoresis experiments were performed three times to obtain a reproducible protein 
pattern and were confirmed in all the experiments by MALDI-TOF MS and MS/MS 
analysis. (a) Coomassie-stained 2D gels from whole cell lysates of PR9 cells under 
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uninduced (-Zn, 0h) and induced (+Zn, 6h) conditions. The encircled spots represent 
proteins identified as identical in all the experiments and as differentially regulated by 
PML-RARα (top), U937 cells under similar conditions were used as Zinc control (bottom).
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(b) Silver-stained 2-D gels under uninduced and induced conditions. (c) an enlarged view 
of some of the protein spots taken from the 2D gel image of Figure 8a and b; a comparison 
in expression values using ProteomWeaver software under uninduced and induced 
conditions are shown. 
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(d)
Warped (0 and 6h) 
=6h
=0h
Non warped (0 and 6h) 
pOP18 
(Ser63) 
OP18 
(e)
Warped (0 and 6h) Nonwarped (0 and 6h) 
X
X
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(f)
(d) PR and (e) U937; proteomWeaver based nonwarped and warped images for uninduced 
(0h) and induced (6h) conditions in a single gel for individual comparison of each spot. 
Warped image were generated automatically by overlaying two individual gels for correct 
matching of protein patterns. (f), Scatter plots to analyze gel similarities among a series of 
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gels. Different gels were matched automatically by the software with a reference gel (gel 1) 
and show a strong correlation (correlation coefficient r, 0.58 and 0.66). 
3.3 Identification of proteins by mass spectrometry based approach: MS-
MS analysis
All the proteins shown to alter in their expression by PML-RARα according 
to gel patterns were identified by MALDI-TOF mass spectrometry (MS). The 
peptide signature of the proteins identified in most cases was validated by 
MS-MS analysis using the Applied Biosystems AB4700 mass spectrometer. 
For example, one of the proteins identified was OP18. The MS spectra with 
m/z ratio for peptides generated are shown for illustration (Fig. 9a). The three 
monoisotopic peaks (shown as arrows in Fig. 9a) were subsequently selected 
for an automated MS-MS fragmentation run. For each precursor ion, a 
fragmented spectrum was generated which revealed the number and location 
of amino acids present in the peptide (Fig. 9b-d). 
The identity of the precursor ions was analysed by comparison with tryptic 
peptides of OP18 (SwissProt accession P16949) generated in a theoretical 
digest with trypsin using ‘prospector.ucsf.edu’. The MS-MS 1388.67 (an 
OP18 tryptic peptide) produces C-terminus fragments (y-ion series) of 175.12, 
272.17, 359.2, 472.29, 585.37, 698.46, 827.50 and 974.57, and N-terminus 
fragments (b-ion series) of 1214.64, 1117.59, 1030.56, 917.47, 804.39, 
691.31, 562.26 and 414.19, which correspond to a sequence 
ASGQAFELILSPR of OP18 (Fig. 9c, compare with Fig. 9e). Likewise, the 
MS-MS 1488.74 (another OP18 tryptic peptide) corresponds to a sequence 
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KLTHKMEANKEN of OP18 (Fig. 9b) and the MS-MS 1052.56 corresponds 
to a sequence ASSDIQVKELEKR of OP18 (Fig. 9d). Using this procedure, 
we could clearly reveal the identity of OP18. The identity of all the proteins 
that were changed in expression by the fusion protein was confirmed this way 
(Fig.9f).
Table 2. Identified proteins that are differentially expressed by PML-RAR -
induction in PR9 cells: MALDI-TOF MS results quantified by proteom 
weaver and confirmed by MS-MS analysis
Protein Spot Score  Mr PI Accession Spot vol. Spot vol. Increase Sequence
KDa                 (-Zn)±SE   (+Zn) ±SE  kDa      coverage%
Proteins upregulated by PML-RARα
RUFY2 Rabip4R      7 72        68.9   5.6     Q96P51          0.56±0.01    0.74±0.01     31.5         18
eIF 5A      9       63        16.6   5.08   IF5A_Hum    0.72±0.19    1.40±0.11     38.5     34
PEBP    11 66        20.4   7.18    1BD9A 0.17±0.05    0.36±0.06     56.6     37
RanBP1    17       70        23.3   5.19    S54290 0.99±0.16    1.75±0.18     61.5     27
Tubulin β-7 chain      22       114      50.1   4.78    S01713 0.29±0.02   0.58±0.12     100     25
Actin, β (fragment)        23       98        41.3   5.55   Q96HG5 0.21±0.01    2.9±0.06       128     47
HSP70    24       262      70.2   5.48    A45871 0.73±0.47    2.00±0.14     172     40
STMN (OP18)    29    132      20      5.77    A40936 1.90±0.07    2.95±0.38     55     25
HSP27    33       140      22.8   5.98    HHHU27 0.81±0.01    1.38±0.09     93.7     58
GRP75    49       153      74.0   5.87    AAA67526 2.43±0.47    4.45±0.45     116     32
ADH    53       62        36.7   6.34    AKA1_Hum 0.25±0.01    0.46±0.02     96     27
Annexin I    54       157      38.7   6.64    ANX1_Hum 0.34±0.02    0.50±0.02     68.7     44
IPYR    56       72 32.2   5.42    AAD24964 0.31±0.01    0.47±0.01     35.2     29
Ub protein ligase       59       69 17.2   6.13    JC4894 0.39±0.01    0.50±0.20     24     26
TBCA_Human    60       66 12.7   5.25    TBCA_Hum 0.48±0.02    0.65±0.01     27     40
Adenylate kinase    114     84 21.6   8.73    JC5893 0.13±0.01    0.60±0.001   117     59
PA28 α chain    140     101 28.8   5.78    A54859 0.44±0.01    0.87±0.06      113     33
PCNA    146     110 29.1   4.57    1AXCE1 0.78±0.01    1.70±0.13      50     36
ROK_Human     *        101 51.2   5.19    S43363 0.14    0.33     24
Prot. Endo.complex     *        67 26.5   4.74    S17521 0.20    0.42                   19
H+-  ATPase     *        101 56.5   5.26    A33370 0.68    1.10                   31
CAF1     *         73 47.9   4.9      S36112 0.11    0.31      20
RNCC protein     *         90 27.2   5.09    CAB46078 0.57    0.79                   34
Tropomyosin     *         177 29.2   4.75    A25530 0.70    1.40     37
PDI     *         208 56.7   5.98    JC5704 0.57 0.85     27
Proteins downregulated by PML-RARα
Thioredoxin    1          93        11.6   4.82   THIO-Hum       1.30±0.17     0.11±0.01     -119        23
Galectin1    2 86  14.9   5.34    LEG1_Hum     1.10±0.10    0.30±0.03     -72.7     35
pOP18***    3 67       17.1   5.77    STN1-Hum 0.77±0.02     0.36±0.01     -53.2     31
hnRNPL    4 97 60.7   6.65    A33616 0.24±0.13     0.16±0.13     -33.3     21
CCT6    5 88 58.4   6.23    S48087 0.91±0.10     0.51±0.01     -43.9     18
Ly-GD1    16 75 23.0   5.1      A47742 3.29±0.01     1.70±0.01     -48.3     31
NAP1    25 85 45.6   4.36    S40510 3.35±0.40     0.63±0.07    -84.3     19
NASP        26 101 49.0   4.35    AAH03113 3.32±0.26     0.80±0.07    -69.1     28
CALR precursor    27 79 48.2   4.29    A37047 4.96±0.11     1.65±0.03    -68.7     19
DnaK mol.chap.    50 212 71.1   5.37    A27077 5.05±0.10     3.60±0.07    -32.6     34
ACP1    52 115 37.9   6.60    S58529         0.52±0.05      0.30±0.02    -44.2     42
EndP precursor    66 274 72.3   5.07    A35954 0.67±0.06     0.37±0.06    -51.7     26
Cofilin    71 66 18.7   8.22   S12632         0.65±0.01      0.05±0.02     -     31
Capping protein         91 140 33.1   5.45    G02639        1.14±0.20     0.85±0.16    -23.8     66
Prolyl hydrox.    92 224 57.1   4.76    CAA28775 1.6±0.00     0.80±0.00    -50.0     44
Rib. Prot. RS    97 82 32.9   4.79    A31233 0.67±0.30     0.90±0.03      -     37
Esterase10    115 93 31.5   6.54    Q9BVJ2 0.46±0.07     0.18±0.01    -32.2     23
Prot. α type    117 140 29.6   6.15    AAH2577 0.40±0.07     0.26±0.07    -46.7     31
41
Pin1    134 94 17.9   7.85    1AK4B 1.02±0.11     0.27±0.05    -62.5     39
LBP    148 104 31.8   4.84    CAA43469 0.78±0.00      0.32±0.00    -58.9     43
ERLP 28     * 81 29.0   6.77    T09549 1.3     0.42 -67.8     28
RBP reg.subunit     * 69 20.1   6.33    014805 1.5     0.46   -69.3     34
*** Phosphor-isomer (Ser63) of OP18
(a)
(b)
(c)
(d)
(e)
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Figure 9: Representative of MALDI-TOF MS and MS MS spectra: (a) the spectra was 
obtained from P/R9 cells for OP18  and (b, c, d)  the MS MS spectra for OP18 peptide are 
detected from 3 precursor ion  selected from MS spectra and (e) tryptic peptide of OP18
(P16949-OP18 sequence) generated in theoretical digest with trypsin using 
prospector.ucsf.edu 
(f)
(f) the spectra was obtained from P/R9 cells for HSP70, eIF, Annexin I and Capping 
protein were shown with the molecular weight calculation (m/Z).
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3.4 PML-RARα iated with changes in cell 
cycle associated proteins 
When compared with control PR9 cells (uninduced), changes in proteins 
associated with cell cycle regulation such as increased levels of oncoprotein18 
(OP18), proliferating cell nuclear antigen (PCNA), heat shock protein70 
(HSP70) and glucose regulated protein75 (GRP75), and decreased expression 
of peptidyl-prolyl isomerase (Pin1) are seen in PML-RARα expressing PR9 
cells (Fig. 10a-d upper panels and Table 2). OP18, a phosphorylation 
responsive microtubule destabilizing protein (Kuntziger et al., 2001; Sobel, 
1991) and PCNA, an essential auxiliary protein for DNA replication and 
repair processes (Kontopidis et al., 2005) have defined roles in cell 
proliferation, and are therefore closely involved in cell cycle. HSP70 shows 
elevated levels in proliferating mammalian cells and a cell cycle dependent 
expression (Helmbrecht et al., 2000). Pin1, an important mitotic regulator is 
known to be overexpressed in malignant cells and its expression is also cell 
cycle-phase dependent (Xu and Manley, 2004). Thus PML-RARα induction 
brings about overlapping functions essential for cell cycle and mitosis 
regulation. As proof-of-principle, we validated our findings by performing 
immunoblots on OP18, HSP70, GRP75, Pin1 (Fig. 10a-10d bottom panels) 
and PCNA (Table 2). No significant change in the expression of OP18 or 
other analysed proteins was observed in the control U937 induced with zinc 
(Fig.10f bottom panel).
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A notable observation seen in PML-RARα induced cells compared with 
control is a presence of more than one protein spot for OP18, one of which is 
increased  (Fig. 8c Spot 29) and the other decreased by the fusion protein (Fig. 
8c Spot 3). This observation was confirmed by 2D-western blotting (Fig. 10e). 
Presumably one of the spots corresponds to a phosphorylated form of OP18 
(pOP18) having a lower isoelectric point (PI). Thus, PML-RARα may 
regulates OP18 at the level of a post-translational modification 
(phosphorylation). As can be seen, in fact this is the case. OP18 in other 
settings has been reported to be regulated by phosphorylation (Beretta et al., 
1993; Leighton et al., 1993; Marklund et al., 1996). Based on the weight of 
these findings, we selected OP18 as a representative of the cell cycle network 
to characterize and understand further the role of PML-RARα in this cellular 
process.
3.5 Retinoic acid degrades PML-RARα expression and overcomes the      
increased OP18 expression
Some proteins that function in cellular defense (e.g; PA28), structural 
organization (e.g.; CapZ) or signal transduction (e.g; Ly-GD1), known to be 
upregulated by RA in NB4 cells, are downregulated by PML-
Likewise, the proteins that function during the initiation and elongation stages 
of the protein synthesis mechanism (e.g.; eIFs), and the chaperones (e.g; 
HSP70), which are downregulated by RA in NB4 cells (Harris, Ozpolat, et al. 
2004), are upregulated by PML-
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effects on the levels of protein in PR9 cells upon zinc induction are 
specifically as a result of the fusion protein. Since, retinoic acid (RA) is 
known to degrade PML-RARα (Yoshida, Kitamura, et al. 1996)  and induce 
differentiation, we first investigated the effect of RA on OP18 expression in 
PR9 cells. A western blot analysis with anti-OP18 antibody revealed increased 
OP18 expression upon PML-RARα induction (Fig. 11 upper panel, lane 2) 
compared with uninduced condition (lane1), consistent with our previous 
result. However, RA alone or in combination with zinc markedly decreases 
OP18 expression (Fig. 11 upper panel, lanes 3-5) below the basal level (lane 
1). Reprobing the same blot with anti-RARα antibody revealed that there was 
no PML-RARα (normally induced by zinc treatment, Fig. 11, lane 2) in cells 
treated with RA (Fig 11, lane 3-5 bottom panel), which is consistent with 
reports showing degradation of PML-RARα with RA. RA in this cell system 
could induce differentiation as evidenced by CD11b expression, a marker of 
myeloid differentiation (data not shown). Thus enhanced OP18 expression in 
this cell system reflects a poor differentiation status. To ensure that the 
expression of PML-RARα does not fall to undetectable levels during the 
course of the experiment, we performed a western blot analysis for the fusion 
protein expression at different time points (data not shown). Furthermore, 
increased OP18 protein levels highly correlate with OP18 mRNA levels in 
PR9 cells (Fig 12) and clinically relevant settings from patients with acute 
myeloid leukemia.
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Figure 10: Comparison of 2-D gel analysis results and western blotting: (a, b, c, d)
induction of PML- 4) 
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GRP75 and decreased expression of Pin1. Each histogram (a-d upper panel) represents 
normalized spot volume shown in table2. (e) 2D Western blot for OP18 from PR9 lysates 
after IEF at pH 3-10 and 2D gel electrophoresis, the proteins on the gel were transferred 
onto PVDF membrane and blotted for OP18 using anti-OP18 antibody (sc-20796 Santa 
Cruz). The numbers underneath denote densitometry values. (f) Zinc induction in U937 
cells leads to no significant change in the expression of the protein (lower panel).The 
histogram represents normalized spot volume for OP18 expressed as mean standard 
deviations for OP18  from 2D gels (Upper panel)
P/Rα
ZnSO
4
RA (10-6 M)
h
OP18
-
-
+
-
-
+
+
+
+
+
0 6 6 126
1       2        3      4        5
β-tubulin
Figure 11: Retinoic acid overcomes expression of PML-RARα and OP18: Immunoblot 
for OP18 using  anti-OP18 antibody (C-20, Santa Cruz) in PR9 cells before and after 
treatment with zinc sulfate and RA at different time points (Uper panel). The blot was 
stripped and reprobed with anti-RARα for the detection PML-RARα (Middel panel) (sc-
551 Santa Cruz) and β-tubulin (lower panel).
3.6 Primary APL patient t(15;17) cells and  PR9 cells express high levels 
of OP18  mRNA as compared to normal bone marrow 
Using microarray (affymetrix), we examined the OP18 mRNA expression 
levels in clinically relevant settings from patients with myeloid leukemia as a 
first step towards deciphering its role in APL. The data revealed increased 
mRNA expression of OP18 PR9 cells after zinc induction and in patients with 
t(15;17) compared to normal bone marrow and other types of leukemia
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(Fig.12 crossed bars). Interestingly, the expression of OP18 mRNA is elevated 
in blasts from patients with a complex aberrant karyotype, which have a 
prognosis similarly poor to the prognosis of APL before the advent of RA, 
suggesting its prognostic significance. The increased OP18 mRNA expression 
cannot be a mere reflection of the heterogeneity of leukemic samples since, 
increased OP18 expression is also observed in our settings using a common, 
clonal cell background, U937 (PR9) when PML-RAR  is induced (Fig. 10e 
2D western). To investigate the transcriptional effect of PML-RAR on the 
OP18 promoter, we performed a transient co-transfection assay in fibroblast 
293T cells with OP18 luciferase reporter, a kind gift from Dr. Herrera (Polzin, 
R. G et al., 2004) and either PML-RARαRARαor PML. The fusion protein 
PML-RARα (Fig. 12b, histogram 2-3) and not PML (histogram 5) or RARα
alone (histogram 6) specifically activated the OP18 luciferase reporter about 
3-fold over the vector only lane (histogram 1) at the highest concentration 
used (Fig. 12b). Importantly, the fusion protein mediated activation of OP18
was retinoic acid sensitive (Fig. 12b, histogram 4). Thus, PML-RARαis a 
potent activator of the OP18 promoter.
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Figure 12: Microarray (affymetrix) data revealed increased mRNA expression of 
OP18 in patients with t(15;17). (a) Affymetrix data showing the mRNA expression values 
of OP18 in different patient samples, n on top of bars represent the number of patients 
evaluated in each subgroup. (b) PML-RARa is a potent activator of the OP18 promoter. 
OP18 luciferase activity in the presence of different amounts (0.2, 0.1 µg) of PML-RARa, 
RARa, or PML expression plasmids. Cells transfected with PML-RARa were also treated 
with 1µM RA 6h post-transfection
3.7 PML-RARα induces a G1 to S-phase transition
We have demonstrated that PML-RARα induction in PR9 cells leads to 
increased OP18 protein levels. OP18 has been shown to have a role in cell 
cycle and mitotic exit (Brattsand et al., 1994; Gavet et al., 1998; Lane and 
50
Ley, 2005; Larsson et al., 1999; Marklund et al., 1994b; Misek et al., 2002). 
The observation that PML-RARα induces OP18 expression, led us to 
speculate about the role of PML-RARα in cell cycle and mitotic exit. So far 
PML-RARα has been shown to block differentiation. This is the first evidence 
showing its role in cell cycle and mitotic exit. We performed cell cycle, 
mitotic index and immunofluorescence experiments to understand the role of 
PML-RARα in the cellular processes mentioned above. Our results revealed 
that the proportion of cells in the S-phase significantly increased in induced 
condition as compared to the uninduced condition at 12h and 24h commitment 
period. On the other hand, the proportion of cells in the G2/M-phase was 
reduced in the induced condition as compared to uninduced condition (Fig. 
13a). The experiments using synchronized cells revealed similar results. When 
PR9 cells were serum starved (0.5% FBS instead of normal 10%) for 24h, 
most of the cells became quiescent. Consequently, the proportion of cells in 
the G0/G1-phase increased dramatically (Fig. 13b). When the cells are 
induced for PML-RARα at 24h commitment period (synchronized condition, 
Fig. 13b right panel), the proportion of cells in the S-phase increased in the 
induced condition compare to uninduced condition, whereas the proportion of 
cells in the G2/M-phase drastically decreased in induced condition compared 
to uninduced condition. At this commitment period, the cells in PML-RARα
induced condition had already exit the G2/M-phase to enter a new cycle 
compared to uninduced condition (Fig. 13b, compare 24h histograms). The 
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data from three independent experiments showing the P value are shown as 
histograms (Fig. 13c). U937 cells under similar conditions were used as Zinc 
control (data not shown). We observed no significant toxicity of PML-RARα
in PR9 cells, consistent with a recent report by Lane et al (Lane & Ley 2005). 
Trypan-blue staining showed a significant increase in cell number under 
induced condition as compared to the uninduced condition observed over a 
period of three days (data not shown). These data indicate that even though 
the cells were arrested, PML-RARα gives them a survival advantage by 
allowing them to divide faster, exit mitosis and enter a new cell cycle. 
3.8 PML-RARα  promotes mitotic exit
Since, it is not possible to differentiate the G2 and M-phase accumulation by 
propidium iodide staining; we substantiated the hypothesis that PML-RARα
commits the cells to exit mitosis faster by mitotic index experiments. 
When the cells are induced for PML-RARα, the proportions of mitotic cells 
were reduced to less than a half (mitotic index 11) as compared to the 
uninduced control cells (mitotic index 23, Fig. 14 compare DAPI panel). 
PML-RARα induced cells exhibit pronounced changes in the mitotic spindle 
structures (composed of tubulin polymers) characteristic of the depolymerised 
non-mitotic state (Fig. 14 compare tubulin panel). Furthermore, 
immunofluorescence staining of OP18 shows increased expression upon 
PML-RARα induction (Fig. 14 compare OP18 panel). Staining with MPM2, a 
marker for mitotic cells further supported our data (data not shown). 
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Figure 13: PML-RARα induces a G1 to S-phase transition: (a&b) Cell cycle 
distribution of PR9 cells before and after PML-RARα induction at the indicated time 
points under asynchronous and synchronous conditions. Cells were serum starved (0.5% 
FBS instead of normal 10%) for 24h and the following day supplied with media containing 
10% FBS. PML-RARα was induced by addition of Zinc and the cell cycle phases were 
analysed at the indicated time points. Cells were washed with PBS and stained for DNA 
with propidium iodide (PI) and analysed for different phases by FACS analysis.
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(c) Cell-cycle analysis was performed using propidium iodide staining. Median values are 
shown and error bars depict standard deviation from 3 independent experiments at the 
indicated time points. The P value was calculated by using student´s t- test by comparing 
the means of two different conditions in each experiment.
M
I
=
1
1
M
I
=
 2
3
OP18
(-Zn)
OP18
(+Zn)(+Zn)
DAPI
(+Zn)
tubulin
(-Zn)
tubulin
(-Zn)
DAPI
M
I
=
1
1
M
I
=
 2
3
54
Figure 14:  PML-RAR  promotes mitotic exit for the cells to enter a new cell cycle. 
Indirect immunofluorescence staining for OP18 and α-tubulin using conjugated antibodies. 
Cells before and after PML-RARα induction were cytocentrifuged on glass slide cover 
slips, fixed with methanol/acetone, permeabilized with 0.3% TritonX , stained with 
respective antibodies (Alexa Fluor, Molecular Probes) and DAPI. The morphology of the 
cells was visualized under fluorescence microscope (100X). Mitotic index (MI) represents 
the quantification values of mitotic cells by counting 150-200 cells. 
3.9 Induction of PML-RARα inhibits the expression of cell cycle    
inhibitors (p21) and increases the CDk2/CDk4 kinase activities 
To elaborate on the role of PML-RARα in the cell cycle, we next investigated 
the effect of PML-RARα induction in PR9 cells upon cell cycle regulatory
proteins. p21, a cell cycle inhibitor and CDK2/CDK4, a cyclin-dependent 
kinase system were an obvious choice in line with their role in G1 to S-phase 
transition. A decrease of the expression of p21 in PML-RARα induced 
condition was observed (Fig.15 a). As could be expected, PML-RARα
decreases the expression of p21, a cyclin dependent kinase inhibitor (CDKIs) 
(Drdova and Vachtenheim, 2005; Liu and Lozano, 2005) which is involved in
mediating growth arrest in the G1 phase of the cell cycle (Lowenheim et al., 
2005). At the same time CDK2/CDK4 kinase activities were increased 
(Fig.15b). These observations suggest that decreased level of CDK inhibitor 
(p21) and the increased activities of CDKs (CDK2/CDK4) contribute to G1 to 
S-phase transition induced by PML-RARα. 
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Figure 15: Induction of PML-RARα inhibits the expression of cell cycle inhibitors p21 
and increases the CDK2/CDK4 kinase activities: (a) immunoblot analysis for p21 from 
whole cell lysates of PR9 cells before and after PML-RAR  induction and (b) In vitro
kinase assay for CDK2 and CDK4. Whole cell lysates were prepared from PR9 cells at the 
indicated time points and CDK2/CDK4 was immunoprecipitated using respective 
antibodies. Histone H1 and Rb-fusion protein were used as substrates for CDK2 and CDK4 
respectively, in the in vitro kinase reaction. (c) an Immunoblot IP control for CDK2 and 
CDK4.
3.10 Knocking down OP18 expression by RNA interference in PR9 cells 
prevents PML-RAR -phase transition 
PML-RARα was clearly able to promote mitotic exit and G1 to S-phase 
transition in PR9 cells, and a correlation between mitotic exit and OP18 
expression was observed. Therefore, to assess specifically for the involvement 
of OP18 in the PML-RARα mediated cell cycle effects, we used RNA 
interference technology to suppress OP18 expression in PR9 cells. PR9 cells 
were transfected with two different small interfering RNAs (siRNA) and 18-
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24h after transfection; cells were treated with zinc to induce PML-RARα. As 
shown as Fig.16, cells that had been transfected with siRNA against OP18 and 
induced for PML-RARα (Fig. 16a, left bottom panel) were unable to exit 
G2/M-phase compared to the control (Fig. 16a, left top panel) at 48h. To 
ensure specificity of the OP18 siRNA in its effects on cell cycle, a scrambled 
sequence was used as a non-silencing control. No significant change in cell 
cycle parameters was observed with non-silencing control (Fig. 16b). The data 
from three independent experiments with the P values are shown as 
histograms (Fig. 16c). These data indicate that siRNA against OP18 is able to 
block PML-RARα mediated mitotic exit. Most interestingly, we observed that 
siRNA against OP18 at early time points of 12h (Fig. 16a left panel) could not 
prevent PML-RARα mediated mitotic exit effects. We reason that this is 
attributable to the long half-life of OP18 (approximately 14h), which is 
supported by the observation that the expression of OP18 is reduced 
completely only 48h after transfection of siRNA (Fig. 16d). Taken together, 
these observations clearly demonstrate that under our experimental settings 
mitotic exit in PR9 cells requires the presence of the PML-RARα fusion 
protein and a consequent increase in OP18 expression. The transfection 
efficiency of siRNA transfected cells measured was greater than 80% using 
rhodamine-conjugated siRNA (Fig. 16e). The data from three independent 
experiments showing P value are showen as histogram.
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Figure 16: siRNA against OP18 overcomes the effects of PML- Cell-cycle 
analysis was performed using propidium iodide staining at 12h and 48h.  (a) RNA 
interference experiment with cell cycle as a read-out. (b) Non-silencing siRNA does not 
overcome PML-RARα mediated cell cycle effects. PML-RARα was induced 18 hours post 
transfection and analyzed for cell cycle profile at different time points of PML-RARα
induction.
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(c) Cell-cycle analysis was performed using propidium iodide staining at 12h and 48h. 
Median values are shown and error bars depict standard deviation from 3 independent 
experiments. The P value was calculated by using student´s t- test by comparing the means 
of two different conditions in each experiment. (d) Immunoblot for OP18 after 48 hours of 
siRNA transfection Shown is a representative experiment of one siRNA. (e) Rhodamine-
conjugated siRNA were used for transfection efficiency. 
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3.11 PML-RARα
cells as well as t(15;17) carrying AML patient samples 
The data presented thus far indicate that PML-RAR  mediates its cell cycle 
effects at the least, through its effects on OP18 level. Previous reports have 
shown the role of OP18 phosphorylation in cell cycle and mitotic exit (Beretta 
et al., 1993; Leighton et al., 1993; Steinmetz et al., 2001). It has been shown 
that phosphorylation of OP18 on Ser63 which is in the α-helical region of 
OP18 disrupts its helical conformation thereby suppressing its binding to 
tubulin (Marklund et al., 1996). Most interestingly, this hypothesis favored
our previous assumption that the effects of PML-RARα could be regulated at 
the level of posttranslational modification, which was based on the 
observation that the fusion protein led to a decrease in an isoform of OP18.
We have observed a decrease in phosphorylation of OP18 upon PML-RARα
induction (Fig. 8a, spot3). To confirm this observation, we performed a 
normal and a 2D-western blotting using phosphospecific (Ser63) anti-OP18 
antibody. Our results revealed a significant decrease in the level of OP18 
phosphorylated on residue Ser63 by PML-RARα in PR9 cells both by normal 
(Fig. 17a) and a 2D-western analysis (Fig. 17b) consistent with 2D gel results. 
There was no significant effect on the level of Ser63 phosphorylation in U937 
cells used as zinc control (Fig. 17a, bottom panel). A similar result was 
obtained from AML M3 (APL) patients compared to normal bone marrow 
(nBM) and other AML samples (Fig. 17c). Furthermore, the induction of 
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PML-RARα led to a dramatic increase in the expression of okadaic acid 
sensitive phosphatase PP2A and also a slight increase in the expression of 
phosphatase PP2BA (Fig. 17d). PML-RARα could no longer induce PP2A 
when the cells were treated with 0.5 µM okadaic acid prior to the treatment of 
zinc to induce PML-RARα  (Fig. 17d, compare lane 1 and 2 right panel).
Under these conditions (0.5 µM okadaic acid and PML-RARα), we however, 
observed increased level of Ser63 phosphorylation of OP18 compared with no 
okadaic acid condition (Fig. 17e, compare lane 2 and 3). Taken together, these 
data suggest that reduced phosphorylation level of OP18 by PML-RARα
involves the Ser/Thr phosphatase pathway. Thus, PML-RARα not only 
initiates its effects (in this case cell cycle) at the protein level of OP18 but also 
at the level of post-translational modification of OP18 levels (in this case 
phosphorylation).
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Figure 17: PML/RAR dephosphorylate OP18 at Ser63.  (a), Comparison of expression 
of pOP18 defined by 2-dimensional gel analysis (a, upper right panel) and immunobloting 
for phospho-OP18 (Ser63) using phospho-Ser63 specific antibody (sc-12949, Santa Cruz) 
before and after PML-RARα induction in PR9 cells and U937 cells as zinc control (a, left 
upper and lower panel). (b), 2-D immunoblotting for phospho-OP18 (Ser63) in PR9 cells 
after six hours of induction. (c), Immunoblot analysis in AML patient samples for phospho-
OP18 (Ser63) and OP18. nBM stands for normal bone marrow, and M0, M1, M2, M3 and 
M4 represent different AML FAB subtypes. 
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PML-RARα decreases the expression of phosphatase PP2A and PP2BA.  (d), Immunoblot 
for PP2A and PP2BA before and after PML-RARα induction in PR9 cells (left panel), and 
in the presence and absence of okadaic acid (right panel). (e), Immunoblot for PP2A and 
phospho-OP18 (Ser63) after treatment with zinc sulfate and okadaic acid. 0.5 µM okadaic 
acid was used to inhibit the phosphatases 1-2 h before zinc sulfate treatment prior to the 
induction of PML-RARα.
3.12 Reduced phosphorylation of OP18 by the PML-
protein at a single Ser63 residue is sufficient for its mitotic exit effects 
To further characterize the role of OP18 (Ser63) dephosphorylation in APL, 
we generated a phosphorylation-deficient mutant Serine to Alanine 
(S63→A63; S63A) and a constitutively phosphorylated mutant Serine to 
Aspartic acid (S63→D63; S63D). Overexpression of these mutants in PR9 
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cells had profound but opposite effects on cell cycle and mitotic exit events. 
Overexpression of phosphorylation-deficient mutant (S63A) could mimic the 
effects of PML-RARα on mitotic exit whereas the constitutive-
phosphorylation mutant S63D resulted in a mitotic block at 12h commitment 
periods. Comparing the data from untransfected PR9 cells (Fig.18a left panel) 
with S63A transfected cells (Middle panel) clearly demonstrates that the 
phosphorylation-deficient mutant mimics the effects of PML-RARα ( leads 
to mitotic exit). In contrast, results from PR9 cells transfected with a 
constitutively phosphorylated mutant (S63D) revealed the opposite. The 
proportion of cells in the G2/M-phase was significantly higher (Fig.18a right 
panel) in S63D transfected cells at 12h commitment period. Similar results 
were obtained at 24h commitment period. The data from three independent 
experiments with P value are shown as histograms (Fig.18d). Thus, 
constitutively active mutant of OP18 in PR9 results in a mitotic block in 
contrast to phosphorylation deficient mutant, which leads to a mitotic exit. In 
other words, presence of the constitutive phosphorylation of OP18 is able to 
prevent PML-RARα mediated mitotic exit.  These data clearly indicate that 
dephosphorylation of OP18 at Ser63 is necessary and sufficient for PML-
RAR  mediated mitotic exit since the constitutively active mutant is able to 
overcome PML-RAR effects. Mitotic index measurements showed similar 
results using S63A-mut compared to S63D-mut upon induction of PML-
RAR  (data not shown). 
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To rule out cell line specificity and overcome the potential 
disadvantages of the otherwise simplistic model system, in its feasibility to 
match the clinical situation, we confirmed our data in APL cell line NB4 (Fig. 
18b) as well as APL patient samples (Fig.18c). In a similar manner as 
described for PR9 cells, NB4 cells were transfected with the mutants and cell 
cycle parameters analyzed.  As it is shown in Fig.18b, NB4 cells transfected 
with S63A-mut exhibit an increased proportion of cells in the S-phase and a 
decreased proportion of cells in the G2/M-phase (Fig.18b middle panel) 
compared with untransfected control ( Fig. 18b left panel). In contrast, NB4 
cells transfected with S63D-mut exhibit an increased proportion of cells in the 
G2/M-phase (Fig.18b right panel) compared with untransfected control (Fig. 
18b left panel). These effects are similar to those observed for PML-RARα in 
PR9 cells. This is not surprising given the fact that untransfected NB4 cells 
(which have PML-RARα translocation) would be expected to have less 
proportion of cells in the G2/M-phase as proposed by our hypothesis. Our 
results demonstrate a proof-of-principle. Our observations in this study point 
to the fact that cell cycle and mitotic exit effects are specific for the fusion 
protein studied, irrespective of the cell line models used. To extend our 
hypothesis from APL cell line model systems to the primary APL cells, we 
took advantage of the nucleofection technology (AMAXA) to transfect S63A-
mut and S63D-mut in patients with newly diagnosed disease. The cell cycle 
profile was evaluated 12h post-transfection. We observed that untransfected 
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and S63A-mut transfected primary APL cells show a very few proportion of 
cells in the G2/M-phase (18c, left and middle panel). Contrary to this, S63D-
mut transfected primary APL cells show a greater proportion of cells in the 
G2/M-phase (Fig.18c, right panle) giving a further support to our hypothesis. 
To rule out the possibility that the cell cycle alterations might be due to zinc 
effects, we show that zinc induction has no significant effect on the cell cycle 
in U937 cells used as control under our experimental settings compared with 
PR9 cells (data not shown). Taken together, our data demonstrates that OP18 
is an important downstream target of PML-RARα and indicates that 
phosphorylation at Ser63 is not sufficient to explain PML-RARα effects on 
mitotic exit but decreased level of OP18 phosphorylation at Ser63 plays an 
important role in the fusion protein mediated effects on cell cycle since, the 
constitutively active Ser63 OP18 mutant is able to prevent the effects.
Untransfected
G0/G1: 96
S:          2
G2/M:  2
G0/G1: 82
S:          8
G2/M:  5
G0/G1: 75
S:          3
G2/M:  23
S63A_mut S63D_mut
APL (M3)
Untransfected
G0/G1: 44
S:          16
G2/M:  46
G0/G1: 42
S:          27
G2/M:  38
G0/G1: 37
S:          13
G2/M:  55
S63A_mut S63D_mut
NB4(b)
(c)
PR9(a)
G0/G1: 40%
S:          11
G2/M:  49
Untransfected
(
+
Z
n
)
G0/G1: 57
S:          12
G2/M:  33
S63A_mut
(
+
Z
n
)
G0/G1: 18
S:          11
G2/M:  72
S63D_mut
(
+
Z
n
)
(
+
Z
n
)
(
+
Z
n
)
(
+
Z
n
)
66
Untransfected
G0/G1: 96
S:          2
G2/M:  2
G0/G1: 82
S:          8
G2/M:  5
G0/G1: 75
S:          3
G2/M:  23
S63A_mut S63D_mut
APL (M3)
Untransfected
G0/G1: 44
S:          16
G2/M:  46
G0/G1: 42
S:          27
G2/M:  38
G0/G1: 37
S:          13
G2/M:  55
S63A_mut S63D_mut
NB4(b)
(c)
PR9(a)
G0/G1: 40%
S:          11
G2/M:  49
Untransfected
(
+
Z
n
)
G0/G1: 57
S:          12
G2/M:  33
S63A_mut
(
+
Z
n
)
G0/G1: 18
S:          11
G2/M:  72
S63D_mut
(
+
Z
n
)
(
+
Z
n
)
(
+
Z
n
)
(
+
Z
n
)
Figure 18: Dephosphorylation of OP18 at Ser63 is important for PML-
RARα mediated cell cycle effects in PR9 cells, in NB4 cells and APL patients. (a) Cell-
cycle analysis was performed using propidium iodide staining after 12 hour in PR9 cells 
overexpressing a phosphorylation-deficient mutant (S63A-mut) and a constitutively active 
mutant (S63D-mut) of OP18. Cells were transfected with the mutants (generated as 
described in Methods) using effectene (Qiagen), induced for PML-RARα with Zinc after 
12 hours analysed for cell cycle phases. (b) Cell cycle profile in NB4 cells overexpressing 
S63A and S63D OP18 mutants. (c) Cell cycle profile in fresh APL patient samples 
overexpressing S63A and S63D OP18 mutants. Fresh samples were transfected with the 
mutants using Nucleofector Kit (AMAXA) and then analyzed for their cell cycle phases 14 
hours post transfection.
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(d) Cell-cycle analysis was performed using propidium iodide staining in PR9 cells at 12h 
and 24h. Median values are shown and error bars depict standard deviation from 3 
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independent experiments. The P value was calculated by using student´s t- test by 
comparing the means of three different conditions in each experiment.
In summary, we conclude that PML-RARα brings about overlapping 
functions essential for cell cycle and mitosis regulation. The regulation of 
OP18 expression and phosphorylation by PML-RARα (Fig.17 and 18) play a 
major role, albeit other mechanisms cannot be ruled out in the effects of the 
fusion protein on cell cycle.   
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4. Discussion 
Recent advance in proteomics offer opportunities to rapidly identify new 
biomarkers or pattern of markers for the early detection and diagnosis of 
cancer and to monitor the therapeutic efficacy and toxicity of treatment used 
to improve long term survival of patients. The characterization of 
leukemogenesis associated genetic alterations, such as the combined presence 
of activating mutation of genes together with altered function of transcription 
factors, and the documented impact of these mutations upon prognosis of 
AML as well as APL, suggests AML or APL as a primary candidate for 
proof-of principle studies with new high throughput protein analysis 
techniques.
The mechanism by which PML-RAR  fusion protein causes an APL 
phenotype remains largely unknown. Although the role of Neutrophil elastase 
in facilitating the leukemogenic potential of PML-RAR  has been reported 
(Lane and Ley, 2003; Lane and Ley, 2005), other factors within a cell that 
collaborate with PML-RAR  to initiate the disease have not been described. 
The identification of proteins and/or protein pathways regulated by PML-
RAR  on a global level is critical to gain insights into the mechanism of how 
the cells become blocked at a particular differentiation step. Microarray 
analysis has been used to investigate thousands of RNA expression levels and 
to identify patterns associated with biological characteristics (Beer et al., 
2002; Bhattacharjee et al., 2001; Carbone, 1997; Garber et al., 2001). 
However, mRNA expression is not correlated with protein expression. 
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Therefore, such analysis can not detect important post translational 
modifications of proteins (Phosphorylation, Glycosylation or Sumoylation), 
all of which are important processes in determining protein function (Garrels 
et al., 1997; Wilkins et al., 1996). 
In this study, we have applied a mass spectrometry-based proteomic 
analysis approach to identify both direct target proteins and the downstream 
effectors of the PML-RAR  fusion protein. We hypothesized that 
identification of the target proteins of the PML-RAR  fusion protein may be a 
useful tool to elucidate the molecular mechanisms of the fusion protein in 
leukemogenesis and a fruitful line of inquiry for developing novel therapies 
for the treatment of leukemia. To address this question, we used an inducible
in-vitro APL cell line model system, the PR9 cell line. The rationale was that 
expression of the fusion protein in this model system is not toxic and 
apoptogenic, and is comparable to that of APL blasts (Grignani, Ferrucci, et 
al. 1993). The expression of PML-RAR  in other systems has been reported 
to be toxic and lead to apoptosis (Ferrucci et al., 1997; Lane and Ley, 2003; 
Walter et al., 2004), which surprisingly would not favor leukemogenesis 
associated with the fusion protein. 
Our data suggested that PML-RAR  potentiates proteins involved in 
cell cycle and mitosis regulation. Based on this we have unraveled a novel 
role for the fusion protein PML-RAR  in mitotic exit and G1 to S-phase 
transition. Furthermore, we demonstrate that increased expression and 
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decreased Ser63 phosphorylation of OP18 is important for cell cycle effects of 
PML-RARα. We show that significant differences exist in the PML-RAR -
mediated effects on the proteome. We show that PML-RAR  induction brings 
about overlapping functions essential for cell cycle and mitosis regulation. For 
example, increased levels of oncoprotein18 (OP18), heat shock protein70 
(HSP70) and glucose regulated protein75 (GRP75), and decreased expression 
of peptidyl-prolyl isomerase (Pin1) are seen in PML-RAR  expressing PR9 
cells. This observation is important as this formed the basis of our hypothesis 
that PML-RAR  could have a positive effect on cell cycle progression so as to 
favor leukemogenesis since these proteins have known roles in cell cycle and 
mitosis regulation. OP18 is highly expressed in leukemic blasts (Melhem, Zhu 
et al. 1991; Roos, Brattsand et al. 1993). Although the exact role of increased 
OP18 expression in various cancers remains unclear, evidence of the role of 
OP18 in various cellular processes (Grignani et al., 1993b; Melhem et al., 
1991; Roos et al., 1993)  led us to further characterize its role in APL. Based 
on the observation that OP18 (Fig. 8a, Spot 29) and its phosphoisoform (Fig. 
8a, Spot 3) were increased and decreased in their expression by PML-
respectively. The role of OP18 as a mitotic regulator that a function via its 
ability to modulate microtubule stability has also been reported (Mistry & 
Atweh 2002). The fact that in cells PCNA and p21 can participate in 
quaternary complexes with CDK4/cyclin D1(Xiong, Zhang, et al. 1992), and 
that it is required absolutely for cell proliferation suggests its contribution to 
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the coordination of cell cycle progression and DNA replication. Experimental 
evidence positions heat shock protein family (HSP70 and GRP75) as cancer-
relevant survival proteins. These so called chaperones show a correlation of 
their expression with increased cell proliferation and poor differentiation 
(Rohde, Daugaard, et al. 2005, Helmbrecht, Zeise, et al. 2000). HSP70 
overexpression has been shown to shorten G2 cell cycle arrest in doxorubicin-
mediated cytotoxicity, thereby showing a one-to-one link with the cell cycle.
It has been shown that pin1 expression is increased in varies types of 
cancers and it has been reported to be involved in cell cycle progression (Bao 
et al., 2004; Wulf et al., 2004). Moreover, Pin1 shows a variable behaviour 
during different phases of cell cycle, for example during G1 phase of the cell 
cycle its expression is enhanced while as it decrease in expression during S 
phase (Zhu et al., 2004). Here we demonstrated that up on PML-RARα
induction the expression of Pin1 goes down and correspondingly the 
proportion of cells in the S phase increase. Microarray (affymetrix) data 
revealed increased mRNA expression of OP18 in patients with t(15;17) 
compared to normal bone marrow and other types of leukemia. Interestingly, 
the expression of OP18 mRNA is elevated in blasts from patients with a 
complex aberrant karyotype, which have a prognosis similarly poor to the 
prognosis of APL before the advent of retinoic acid. 
Identifying retinoid target genes is an important step in developing a 
mechanistic understanding of RA effects in APL. Retinoic acid is known to 
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degrade PML-RAR (Yoshida et al., 1996). Proteomic analysis data 
previously demonstrated an increased OP18 protein expression in cells 
expressing the PML-RAR fusion protein, which was downregulated by 
treatment of cells with RA (Pitha-Rowe et al., 2003). This reinforced the 
identification of OP18 as a PML-RAR target and suggested that regulation of 
OP18 may be one major axis of the fusion protein function. OP18 is regulated 
by both transcriptional and post-transcriptional mechanisms. The OP18 gene 
is a direct target of the E2F family of transcription factors (Polager & 
Ginsberg 2003) and activation of OP18 by PML-RAR  is very unlikely to be 
a direct transcriptional effect. We also show that PML-RARα is a potent 
activator of the OP18 promoter. Since, the OP18 promoter contains RARE 
sequence; it is possible that PML-RARα might bind to the OP18 promoter 
directly to regulate its transcription. However, this needs further experimental 
evidence. The mechanism by which the PML-RAR  fusion protein regulates 
OP18 remains to be determined. One possible hypothesis would be regulation 
at the level of post-translational modification, which in fact is the case. We 
demonstrate that PML-RAR regulates OP18 at the level of phosphorylation. 
So far PML-RAR  has been shown to block differentiation. This is the first 
evidence showing its direct role in cell cycle and mitotic exit. Using three 
independent methods (propidium iodide staining, mitotic index measurements 
and MPM2 staining), we have demonstrated that PML-RAR induction in 
PR9 cells leads to mitotic exit and G1 to S-phase transition. Our data indicate 
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that PML-RAR  gives cells a proliferative advantage by allowing them to 
divide faster, exit mitosis and enter a new cell cycle. The enhanced 
proliferative potential and survival role of PML-RAR  has been proposed to 
occur by direct action on extremely different molecular targets: transcriptional 
regulation of RAR targets genes and regulation of p53 stability. p53, a tumor
suppressor and its target p21, a cell cycle inhibitor are both relevant to cell 
cycle regulation. The modulation of p53 (Insinga, Pelicci, et al. 2005) and p21 
(Casini & Pelicci 1999) functions and the induction of cyclin A1 mRNA 
levels in leukemic cell lines by PML-RAR (Muller, Yang, et al. 2000)
suggested a possible role of the fusion protein in cell cycle regulation. This is 
a reasonable assumption given the fact that in murine models of PML-RARα
the effects of fusion protein on the differentiation program cannot be 
explained solely by their ability to block differentiation (Minucci, Monestiroli, 
et al. 2002; Westervelt & Ley 1999). Thus, the positive effect of the fusion 
protein PML-RAR  on the cell cycle would favour leukemogenesis. MPM2 
specifically recognizes a subset of mitosis specific phosphoproteins and 
widely used as a marker for mitotic cells (Kishi et al., 2001) or a marker of M 
phase in the cell cycle (El-Khodor et al., 2003).  However, at 24 and 48h of 
induction, we could not detect any protein bands, indicating an exit from 
mitosis. Consistent with these data, we also observed that PML-RAR
decreases the expression of p21. It has been shown that p21 is one of the 
cyclin dependent kinase inhibitor (CDKIs) (Drdova and Vachtenheim, 2005; 
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Liu and Lozano, 2005) which is involved in mediating growth arrest in the G1 
phase of the cell cycle (Lowenheim et al., 2005). In addition CDK2/CDK4 
kinase activities were increased at the same time. Together these data explain 
why blasts carrying the translocation t(15; 17) are unable to differentiate after 
mitosis, since the fusion protein commits them to exit this phase faster and 
enter a new cell cycle. PML-RAR  might thus function to coordinate mitotic 
exit and differentiation block resulting in an enhanced proliferative potential 
of the APL blasts. Despite this, we do not yet know whether the commitment 
by the fusion protein to promote mitotic exit is directly linked to a block in 
differentiation. Further study will be required to address this question. We 
further demonstrate that under our experimental settings mitotic exit in PR9 
cells requires the presence of the PML-RAR fusion protein, and an increase 
in OP18 expression represents an important downstream step in PML-RAR
mediated mitotic exit since siRNA against OP18 was able to block the PML-
RAR  effects. In addition, the effects of PML-RAR  on mitotic spindle 
structures (microtubule dynamics and mitotic exit) can be attributed to 
increased OP18 expression. Overexpression of OP18 dramatically shifts the 
equilibrium between free tubulin dimers and microtubules in the direction of 
free tubulin dimers, thereby causing microtubule destabilization (Larsson, 
Marklund, et al. 1997). Furthermore, changes in OP18 expression are 
observed due to the activation of p53, which results in a cell cycle arrest at 
G2/M (Ahn, Murphy, et al. 1999, Johnsen, Aurelio, et al. 2000) and by 
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overexpression of p21 (Steinman, Yaroslavskiy, et al. 2000). Interestingly, 
both p53 and p21 are known targets of PML–RAR  (Casini & Pelicci 1999, 
Insinga, Pelicci, et al. 2005). Thus, OP18 is an important regulatory protein 
and may represent an important target for leukemogenic proteins that regulate 
cell cycle. 
The regulation of protein function by posttranslational modification is 
likely to be protein-specific. In addition Protein phosphorilation-
dephosphorylation is the most common form of posttranslational modification 
used to regulate cell function. For the regulation at post-translational 
modification level, sumoylation of PML (Zhu, Zhou, et al. 2005) and 
acetylation of p53 by PML-RAR (Insinga, Pelicci, et al. 2005) has been 
recently reported. It has been reported that during cell cycle progression, 
OP18 is invariably regulated by phosphorylation on four distinct Serin
residues in intact cells, namely, Ser16, -25, -38, and Ser63 (Leighton, Curmi, 
et al,Beretta, Dubois, et al. 1995,Andersen, Ashford, et al. 1997). In-vitro and 
in-vivo studies have demonstrated that OP18 becomes highly phosphorylated 
during mitosis thereby turning off its microtubule destabilizing activity 
(Marklund, Larsson, et al. 1996). Consistent with the previous report that, 
phosphorylation of OP18  regulates its biological actions and reduce its 
affinity for tubulin (Beretta et al., 1993; Leighton et al., 1993; Marklund et al., 
1996; Steinmetz et al., 2001; Zada et al., 2003) and OP18 enhance its action 
on microtubule dynamic, which allows for progression of mitosis (Curmi et 
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al., 1999; Wittmann et al., 2004). Our results from 1D and 2D western blot 
analysis using a phospho-specific Ser63 anti-OP18 antibody revealed a 
decrease in the expression of Ser63 phospho-isomer of OP18 implying that 
PML-RARα could regulate OP18 at the level of phosphorylation. To further 
understand the importance of this observation, the cell cycle as a read out for 
the effects of PML-RARα was a reasonable assumption given the fact that the 
overall activities of PML-RARα may not rely only on its ability to affect 
myeloid differentiation. Moreover, the role of PML-RARα in cell cycle 
control remains unclear and has not been thoroughly investigated so far. This 
novel assumption supports the hypothesis that the dominant negative action of 
PML-RARα on PML could result in a shortening of the transition through the 
cell cycle. Pml-/- cells are reported to have an increased proliferative potential 
in view of a faster transition through the G1-phase of the cell cycle (Pandolfi, 
2001). Our results from cell cycle analysis are in agreement with the proposed 
dominant negative function of PML-RARα on PML effects on cell cycle. 
Thus, indirect positive effect of PML-RARα on cell cycle would favor 
leukemogenesis.
Our results demonstrate the importance of decreased phosphorylation of 
OP18 at Ser63 in PML-RARα mediated effects on cell cycle. Since a 
constitutively phosphorylated Ser63 mutant of OP18 prevented the cell cycle 
effects of PML-RARα compared to a phosphorylation-deficient mutant. We 
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concluded that reduced phosphorylation of OP18 by the PML-RARα fusion 
protein at a single Ser63 residue is sufficient and important for its effects on 
cell cycle. This reduced phosphorylation might be due to increased activities 
of the Ser/Thr phosphatases PP2A and PP2BA.  It has already been reported 
that, the activity of Serin/threonine protein phosphatase (PP2A, PP2BA) are 
potential targets for novel therapeutic with applications in many diseases, 
including cancer (Klumpp and Krieglstein, 2002) and the expressions level in 
leukemic blasts is low (Yamamoto et al., 1999). The fact that okadaic acid 
prevented both PML-RARα mediated increased PP2A phosphatase expression 
as well as decreased Ser63 phosphorylation level of OP18, led us to conclude 
that decreased phosphorylation occurs via this phosphatase pathway. In fact it 
has been suggested that protein phosphatases are responsible for 
dephosphorylating OP18 as cells enter a new cell cycle (Mistry et al., 1998). 
Decreased phosphorylation of OP18 on Ser63 would consequently favor
microtubule destabilization and a mitotic exit induced by PML-RAR as 
proposed by our previous results. Although the role of other phosphorylation 
sites has also been proposed in mitosis regulation we demonstrate that reduced 
phosphorylation of OP18 by the PML-RAR fusion protein at a single Ser63 
residue is sufficient for its mitotic exit effects since the constitutively 
phosphorylated mutant blocks the effects of PML-RAR  (results in mitotic 
block) compared to a phosphorylation-deficient mutant (results in mitotic 
exit). The role of other phosphorylation sites in PML-RAR  mediated mitotic 
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exit remains to be determined. Decreased phosphorylation of OP18 on Ser63 
would consequently affect cell cycle in a manner as proposed by our results 
in APL patient cells, PR9 and NB4 cells. Decreased phosphorylation of OP18 
during mitotic exit induced by the PML-RAR  fusion protein could in turn, 
contribute to an increased non-phosphorylated form of OP18 (Fig. 8a, spot 
29), in support with a model proposed by Mistry et.al, (Mistry & Atweh 
2001). Therefor, our data indicated that PML-RAR  mediates its cell cycle 
effects not only at the level of OP18 expression, but at the level of a post-
translational modification as well.
In summary, on the basis of our findings we propose a model (Fig.19)) 
wherein, in the presence of PML-RARα, decreased phosphorylation of OP18 
at Ser63 via the PP2A phosphatase pathway would ensue a cell (blast) to exit 
mitosis thereby increasing a nonphosphorylated pool of OP18 since, a 
constitutively-phosphorylated mutant or siRNA against OP18 results in a 
mitotic block. Our data provides a conceptual advance in scientific 
understanding of a human disease by suggesting that targeting proteins of the 
mitotic apparatus may represent a therapeutic option for treatment of APL and 
other AML subtypes.
Thus, proteomic study coupled with functional analysis has clearly 
provided a framework towards understanding of the systems biology of APL 
and might serve as a useful tool for elucidating multiple pathways/cascades in 
the biology of other diseases.
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Figure 19: Model: our model shows that, how PML-RARα promotes cell cycle to exit 
mitosis by increasing expression of OP18 and down regulation of pOP18 at Ser63 by PP2A 
phosphatase thereby inhibiting differentiation. .
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5. Summary
We applied mass spectrometry based approach to explore the proteins 
differentially regulated by PML-RARα a translocation characteristic of acute 
promyelocytic leukemia (APL). Differentialy expressed proteins, a number of 
which are related to cell cycle function, including OP18, HSP70, GRP75 and 
Pin1 were identified by mass spectrometry. Further analysis of the OP18 
pathway indicated that mRNA expression of OP18 was higher in APL patients 
and the increased OP18 protein expression upon PML-RARα induction was 
overcome by retinoic acid treatment. PML-RARα induced cell cycle 
progression and led to mitotic exit. RNA interference experiments revealed 
that siRNA against OP18 overcomes PML-RARα effects on cell cycle 
progression. In addition to increased OP18 expression by PML-RARα, 2D gel 
electrophoresis revealed an isomer of OP18, subsequently confirmed as Ser63 
phosphomer to be downregulated by PML-RARα. Based on these findings, 
point mutation experiments indicated that decreased phosphorylation of Ser63 
in OP18 is important for PML-RARα mediated cell cycle and mitotic index 
effects since constitutive phosphorylated mutant (Ser63-asp) of OP18 
overcame the PML-RARα effects in U937-PR cells, NB4 and APL patients. 
In summary, our results demonstrate that the effect of PML-RARα on cell 
cycle progression and mitotic exit is via two mechanisms: increasing the 
expression of OP18 and decreasing the phosphorylation of OP18 at Ser63.
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6. Zussamenfasung 
Diese Arbeit nutzt einen auf der Massenspektrometrie fußenden Ansatz, um 
die durch das Fusionsprotein PML-RARα, welches für die akute 
Promyelozytenleukämie (APL) charakteristisch ist, differentiell regulierte
Proteine zu erforschen. Differentiell ausgedrückte Proteine, eine Zahl, von der 
mit Zelle Zyklusfunktion zusammenhängen, einschließlich OP18 HSP70, 
GRP75 und Pin1 wurden durch Massenspektrometrie gekennzeichnet. Die 
weiterführende Analyse des OP18-Pfades ergab, dass die mRNA-Expression 
von OP18 in APL-Patienten erhöht ist und dass die durch PML-RARα
erhöhte Proteinexpression von OP18 durch Retinolsäure gesenkt wird. PML-
RARα induziert eine Progression durch den Zellzyklus und führt zu einem 
Austritt der Zellen aus der Mitose. Experimente mit RNA-Interferenz ergaben, 
dass siRNA gegen OP18 die Effekte von PML-RARα auf den Zellzyklus 
antagonisiert. Zusätzlich zu erhöhter Expression von OP18 durch PML-RARα
zeigte sich in zweidimensionaler Gelektrophorese ein Isomer von OP18, 
welches in Folge als das Ser63 Phosphomer bestätigt werden konnte, als 
supprimiert. Auf diesen Daten basierend zeigten Experimente mit 
Punktmutanten, dass die verminderte Phosphorylierung von Ser63 erheblich 
für den durch PML-RARα vermittelten Austritt aus dem Zellzyklus und die 
Effekte auf den mitotischen Index ist, weil eine konstitutiv phosphorylierte 
Mutante (Ser63Asp) von OP18 die Effekte von PML-RARα in U937-PR9-
Zellen, NB4-Zellen und APL-Patientenproben überwinden konnte. 
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Zusammengefaßt demonstrieren unsere Ergebnisse, dass der Effekt von PML-
RARα auf die Progression der Zelle durch den Zellzyklus und auf den Austritt 
aus der Mitose durch zwei Mechanismen vollzogen wird: die Erhöhung der 
Proteinexpression von OP18 und die Verminderung der Phosphorylierung von 
OP18 an Ser63.
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rd
 2004 in 
Innsbruck, Austria
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th
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10. Appendix
1. Cell culture
RPMI (PAA)
10% Foetal bovine serum (Invitrogen)
100µM Zinc sulphate (ZnSO4) (Sigma)
1% Penicillin/Streptomycin (Gibco)
2. Immunoblot
RIPA laysis buffer (1% NP40, 0.5% Sodium deoxycholate, 0.1% SDS,
0.15M NaCl, 5mM EDTA, 50mM Tris pH8.0 and dH2O)
Phosphates inhibitor cocktail I and II (Sigma, USA)
Proteinase inhibitor (Sigma)
Bradford assay (BioRad Laboratories, Germany)
2x loading dye
1x running buffer and 1x Transfer buffer
Nitrocellulose membrane (Millipore)
1xTBST and 5% milk (Blocking buffer)
2.5% milk in TBST (Washing buffer)
ECL detection Kit (Amersham Biosciences, UK)
Hyper film ECL (Amersham Biosciences, UK)
3. 2D-gel electrophoresis
Urea (Amersham bioscience, EU)
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Urea Lysis buffer (9.8M urea, 1% DTE, 4% CHAPS, 2.5mM EDTA and   
2.5mM EGTA)
Resolyte (Amersham Biosciences)
Bromophenol blue (Sigma, USA)
IPG strips (pH 3-10 and pH 4-7) (Amersham Bioscience, Sweden)
SDS PAGE (Gel running buffer 192mM Glycin, 25mM Tris and 0.5% SDS)
DTE buffer and carbamylation buffer (1M Tris pH6.8, urea, 80% Glycerol)
20% SDS and ddH2O and add one half 0.2g DTE and to the other half 0.25 
iodoacetamide)
4. Colloidal Coomassie blue stain (Sigma, USA)
Fixing: 50% methanol and 10% acetic acid 
Staining: 0.1% Colloidal Coomassie, 2% H3PO4 , 10% Ammonium sulfate
and 20% Methanol
Destining: 25% Methanol
5. Silver nitrate (Merck, Darmsadt, Germany)
Silver stain
50% Methanol, 12% Acetic acid and 37% Formaldehyde
50% Ethanol
200mg/L Sodium thiosulfate (Na2S2O3 5H2O)
2g/L Silver nitrate (AgNO3) and 750µl/L 37% formaldehyde
60g Sodium carbonate (Na2CO3), 5mg Na2S2O3 5H2O and 500µl 
formaldehyde
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50% Methanol and Acetic acid
20% Ethanol and 12% Glycerine
6. Peptides Extraction
Acetonitrile (Aldirch)
50% and 70% Acetonitrile
50mM Ammonium bicarbonate (NH4HCO3) 
Trypsin enzyme reconstituted with ammonium bicarbonate (NH4HCO3)
DHB Matrix 
20% Acetonitrile and 0.1% Trifluoroacetic acid (TFA) (Merck)
20 mg/ml 2.5-dhydroxy-benzoicacid (DHB) (Merck)
20 mg/ml 2-hydroxy-5-methoxy-benzoicacid (Merck)
mix 9:1 DHB:HMB
take 1µl of matrix with 1µl of peptide and spot 0,8µl on an anchor chip plate
CHCA Matrix
50% Acetonitrile and 0.05% TFA (Solvent solution)
8mg of CHCA (Sigma) in 200µl solvent solution
2/3 of solvent solution mix 1/3 of CHCA solution
Apply 0.5µl of matrix to the plate
Add 0.5µl of the sample and dry
7. Mass spectrometry
PMF Reflex III MALD-TOF (Bruker Daltonics)
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MS/MS AB4700 and GPS explorer software (Applied Biosystems)
Mascot database search (Matrix Science)
8. Immunofluoresent
Cytocentrifuge
Glass slides 
P/R9 cells
PBS (PAN)
99% methanol and Acetone (Fixing)
Permeabilized with 0.3% Triton X
Block with 5% FBS in PBG (PBG=% BSA, 0.045% Fish-gelatine in 1X PBS)
Primary antibody (Diluted in PBG and 2.5% FBS) anti-rabbit sc20796 Op18
(Santa Cruz Biotechnology Inc.)
Secondary antibody (Diluted in PBG and 2.5% FBS) (anti mouse α
tubulin) Alexa Fluor (Molecular probes)
488 Chicken anti-rabbit and Alexa Fluor 894 chicken anti-mouse 
IgG (Molecular probes)
4´, 6´-Diamidino-2-phenylindole dihydrochloride( DAPI) (Molecular probes)
9. FACS PI-cell cycle analysis
Propidium Iodide (Sigma, USA)
U937 and P/R9 cells  
Cell lysis buffer 
0.1% Sodium citrate 
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0.1% Triton X-100
20µg/ml Propidium Iodide
10. In-vitro kinase 
Protein A agarose beads (Roche)
Kinase buffer (150mM NaCl, 1mM EDTA, 50mM tris-HCl, pH 7.5, 
10mMMgCl2 and 10mMDTT)
Histone H1 (Upstate, Germany)
Rb-fusion protein (Santa Cruz Biotechnology Inc.)
ATP and [γ-32p] ATP
11. siRNA 
Designed 2 Oligos (Gene accession number NM-203401)
RNAiFect (Qiagen)
Non silencing siRNA
siRNA conjugated to rhodamine
